U.S. patent application number 11/642979 was filed with the patent office on 2007-11-15 for quinazoline derivatives as vegf inhibitors.
This patent application is currently assigned to ASTRAZENECA AB. Invention is credited to Laurent Francois Andre Hennequin, Elaine Sophie Elizabeth Stokes, Andrew Peter Thomas.
Application Number | 20070265286 11/642979 |
Document ID | / |
Family ID | 26153696 |
Filed Date | 2007-11-15 |
United States Patent
Application |
20070265286 |
Kind Code |
A1 |
Thomas; Andrew Peter ; et
al. |
November 15, 2007 |
Quinazoline derivatives as VEGF inhibitors
Abstract
The invention relates to quinazoline derivatives of formula (I),
wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or
C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from
one of the following three groups: 1) C.sub.1-5alkylR.sup.3
(wherein R.sup.3 is piperidinyl-4-yl which may bear one or two
substituents selected from hydroxy, halogeno, C.sub.1-4alkyl,
C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2)
C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined
hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as
defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl
group may bear one or more substituents selected from hydroxy,
halogeno and amino; and salts thereof; processes for their
preparation, pharmaceutical compositions containing a compound of
formula (I) or a pharmaceutically acceptable salt thereof as active
ingredient. The compounds of formula (I) and the pharmaceutically
acceptable salts thereof inhibit the effects of VEGF, a property of
value in the treatment of a number of disease states including
cancer and rheumatoid arthritis. ##STR1##
Inventors: |
Thomas; Andrew Peter;
(Macclesfield, GB) ; Stokes; Elaine Sophie Elizabeth;
(Macclesfield, GB) ; Hennequin; Laurent Francois
Andre; (Reims, FR) |
Correspondence
Address: |
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON
DC
20004
US
|
Assignee: |
ASTRAZENECA AB
|
Family ID: |
26153696 |
Appl. No.: |
11/642979 |
Filed: |
December 21, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10129336 |
May 3, 2002 |
7173038 |
|
|
PCT/GB00/04181 |
Nov 1, 2000 |
|
|
|
11642979 |
Dec 21, 2006 |
|
|
|
Current U.S.
Class: |
514/266.22 ;
514/266.4; 544/283 |
Current CPC
Class: |
A61P 9/14 20180101; A61P
9/10 20180101; A61P 43/00 20180101; A61P 15/00 20180101; C07D
401/12 20130101; A61P 3/00 20180101; A61P 37/00 20180101; A61P 3/10
20180101; A61P 35/00 20180101; A61P 17/06 20180101; A61P 9/00
20180101; A61P 29/00 20180101; A61P 27/02 20180101; A61P 19/02
20180101 |
Class at
Publication: |
514/266.22 ;
514/266.4; 544/283 |
International
Class: |
A61K 31/517 20060101
A61K031/517; A61P 19/02 20060101 A61P019/02; A61P 3/00 20060101
A61P003/00; A61P 35/00 20060101 A61P035/00; A61P 37/00 20060101
A61P037/00; C07D 239/94 20060101 C07D239/94 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 5, 1999 |
EP |
99402759.7 |
Nov 19, 1999 |
EP |
99402877.7 |
Claims
1-17. (canceled)
18. A method for producing an antiangiogenic and/or vascular
permeability reducing effect in a warm-blooded animal in need
thereof which comprises administering to said animal an effective
amount of a compound of formula I: ##STR19## wherein: m is an
integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl;
X.sup.1 represents --O--; R.sup.2 is selected from one of the
following three groups: 1) C.sub.1-5alkylR.sup.3, wherein R.sup.3
is piperidin-4-yl which may bear one or two substituents selected
from hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and
C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3, wherein R.sup.3 is as
defined herein; 3) C.sub.2-5alkynylR.sup.3, wherein R.sup.3 is as
defined herein; and wherein any alkyl; alkenyl or alkynyl group may
bear one or more substituents selected from hydroxy, halogeno and
amino; or a pharmaceutically acceptable salt thereof.
19. A method for the treatment of a disease selected from the group
consisting of cancer, diabetes, psoriasis, rheumatoid arthritis,
Kaposi's sarcoma, haemangioma, acute and chronic nephropathies,
atheroma, arterial restenosis, autoimmune diseases, acute
inflammation, excessive scar formation and adhesions,
endometriosis, dysfunctional uterine bleeding and ocular diseases
with retinal vessel proliferation, in a warm-blooded animal in need
thereof which comprises administering to said animal an effective
amount of a compound of formula I: ##STR20## wherein: m is an
integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl;
X.sup.1 represents --O--; R.sup.2 is selected from one of the
following three groups: 1) C.sub.1-5alkylR.sup.3, wherein R.sup.3
is piperidin-4-yl which may bear one or two substituents selected
from hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and
C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3, wherein R.sup.3 is as
defined herein; 3) C.sub.2-5alkynylR.sup.3, wherein R.sup.3 is as
defined herein; and wherein any alkyl, alkenyl or alkynyl group may
bear one or more substituents selected from hydroxy, halogeno and
amino; or a pharmaceutically acceptable salt thereof.
20. The method according to claim 19 wherein said disease is
cancer.
21. A method for the treatment of a solid tumour in a warm-blooded
animal in need thereof which comprises administering to said animal
an effective amount of a compound of formula I: ##STR21## wherein:
m is an integer from 1 to 3; R.sup.1 represents halogeno or
C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from
one of the following three groups: 1) C.sub.1-5alkylR.sup.3,
wherein R.sup.3 is piperidin-4-yl which may bear one or two
substituents selected from hydroxy, halogeno, C.sub.1-4alkyl,
C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2)
C.sub.2-5alkenylR.sup.3, wherein R.sup.3 is as defined herein; 3)
C.sub.2-5alkynylR.sup.3, wherein R.sup.3 is as defined herein; and
wherein any alkyl, alkenyl or alkynyl group may bear one or more
substituents selected from hydroxy, halogeno and amino; or a
pharmaceutically acceptable salt thereof.
22. The method according to claim 21 wherein said solid tumour is
associated with VEGF.
23. The method according to claim 21 wherein said solid tumour is
associated with EGF.
24. The method according to claim 21 wherein said solid tumour is
associated with both VEGF and EGF.
25. The method according to claim 21 wherein said solid tumour is
selected from a tumour of the colon, breast, prostate, lung, vulva
or skin.
26. The method according to any one of claims 18, 19 and 21 wherein
in the compound of formula I, the phenyl group together with the
(R.sup.1).sub.m substituent: ##STR22## forms a group selected from
2-fluoro-4-methylphenyl, 4-chloro-2,6-difluorophenyl,
4-bromo-2,6-difluorophenyl, 4-chloro-2-fluorophenyl group and
4-bromo-2-fluorophenyl.
27. The method according to any one of claims 18, 19 and 21 wherein
in the compound of formula I, R.sup.2 is C.sub.1-5alkylR.sup.3.
28. The method according to any one of claims 18, 19 and 21 wherein
in the compound of formula I, R.sup.2 is piperidin-4-ylmethyl in
which the piperidine ring may bear one or two substituents selected
from C.sub.1-4alkyl.
29. The method according to any one of claims 18, 19 and 21 wherein
the compound of formula I is a compound of formula II: ##STR23##
wherein: ma is an integer from 1 to 3; R.sup.1a represents halogeno
or C.sub.1-3alkyl; X.sup.1a represents --O--; R.sup.2a is selected
from one of the following three groups: 1) C.sub.1-5alkylR.sup.3,
wherein R.sup.3 is piperidin-4-yl which may bear one or two
substituents selected from hydroxy, halogeno, C.sub.1-4alkyl,
C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2)
C.sub.2-5alkenylR.sup.3, wherein R.sup.3 is as defined herein; 3)
C.sub.2-5alkynylR.sup.3 wherein R.sup.3 is as defined herein; or a
pharmaceutically acceptable salt thereof.
30. The method according to any one of claims 18, 19 and 21 wherein
the compound of formula I is selected from:
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline,
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline,
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethox-
y)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoli-
ne,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quina-
zoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)qu-
inazoline,
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quina-
zoline, and
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinaz-
oline, or a pharmaceutically acceptable salt thereof.
31. The method according to any one of claims 18, 19 and 21 wherein
the compound of formula I is selected from:
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline,
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline, and
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethox-
y)quinazoline, or a pharmaceutically acceptable salt thereof.
32. The method according to any one of claims 18, 19 and 21 wherein
the compound of formula I is selected from:
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline, or a pharmaceutically acceptable salt thereof.
Description
[0001] The present invention relates to quinazoline derivatives,
processes for their preparation, pharmaceutical compositions
containing them as active ingredient, methods for the treatment of
disease states associated with angiogenesis and/or increased
vascular permeability, to their use as medicaments and to their use
in the manufacture of medicaments for use in the production of
antiangiogenic and/or vascular permeability reducing effects in
warm-blooded animals such as humans.
[0002] Normal angiogenesis plays an important role in a variety of
processes including embryonic development, wound healing and
several components of female reproductive function. Undesirable or
pathological angiogenesis has been associated with disease states
including diabetic retinopathy, psoriasis, cancer, rheumatoid
arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al,
1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature
Medicine 1: 27-31). Alteration of vascular permeability is thought
to play a role in both normal and pathological physiological
processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837;
Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324).
Several polypeptides with in vitro endothelial cell growth
promoting activity have been identified-including, acidic and basic
fibroblast growth factors (aFGF & bFGF) and vascular
endothelial growth factor (VEGF). By virtue of the restricted
expression of its receptors, the growth factor activity of VEGF, in
contrast to that of the FGFs, is relatively specific towards
endothelial cells. Recent evidence indicates that VEGF is an
important stimulator of both normal and pathological angiogenesis
(Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al,
1995, Breast Cancer Research and Treatment, 36:139-155) and
vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264:
20017-20024). Antagonism of VEGF action by sequestration of VEGF
with antibody can result in inhibition of tumour growth (Kim et al,
1993, Nature 362: 841-844).
[0003] Receptor tyrosine kinases (RTKs) are important in the
transmission of biochemical signals across the plasma membrane of
cells. These transmembrane molecules characteristically consist of
an extracellular ligand-binding domain connected through a segment
in the plasma membrane to an intracellular tyrosine kinase domain.
Binding of ligand to the receptor results in stimulation of the
receptor-associated tyrosine kinase activity which leads to
phosphorylation of tyrosine residues on both the receptor and other
intracellular molecules. These changes in tyrosine phosphorylation
initiate a signalling cascade leading to a variety of cellular
responses. To date, at least nineteen distinct RTK subfamilies,
defined by amino acid sequence homology, have been identified. One
of these subfamilies is presently comprised by the fms-like
tyrosine kinase receptor, Flt or Flt1, the kinase insert
domain-containing receptor, KDR (also referred to as Flk-1), and
another fms-like tyrosine kinase receptor, Flt4. Two of these
related RTKs, Flt and KDR, have been shown to bind VEGF with high
affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al,
1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding
of VEGF to these receptors expressed in heterologous cells has been
associated with changes in the tyrosine phosphorylation status of
cellular proteins and calcium fluxes.
[0004] Quinazoline derivatives which are inhibitors of VEGF
receptor tyrosine kinase are described in International Patent
Applications Publication Nos. WO 97/30035 and WO 98/13354. In WO
97/30035 and WO 98/13354 compounds are described which possess
activity against VEGF receptor tyrosine kinase whilst possessing
some activity against EGF receptor tyrosine kinase.
[0005] Compounds of the present invention fall within the broad
general disclosure of WO 97/30035 and WO 98/13354. We have found
that compounds of the present invention possess very good
inhibitory activity against VEGF receptor tyrosine kinase.
Compounds of the present invention, which have been tested, show in
vivo activity against a range of tumour xenografts in mice.
Compounds of the present invention possess a beneficial
toxicological profile when tested over 14 days in rats. Compounds
of the present invention possess very good inhibitory activity
against VEGF receptor tyrosine kinase, show in vivo activity
against a range of tumour xenografts in mice and possess a
beneficial toxicological profile when tested over 14 days in
rats.
[0006] Compounds of the present invention inhibit the effects of
VEGF, a property of value in the treatment of disease states
associated with angiogenesis and/or increased vascular permeability
such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's
sarcoma, haemangioma, acute and chronic nephropathies, atheroma,
arterial restenosis, autoimmune diseases, acute inflammation,
excessive scar formation and adhesions, endometriosis,
dysfunctional uterine bleeding and ocular diseases with retinal
vessel proliferation.
[0007] Compounds of the present invention possess good activity
against VEGF receptor tyrosine kinase whilst possessing some
activity against EGF receptor tyrosine kinase. Furthermore, some
compounds of the present invention, possess substantially higher
potency against VEGF receptor tyrosine kinase than against EGF
receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. While
we do not wish to be bound by theoretical considerations such
compounds may for example be of interest in treating tumours which
are associated with VEGF, especially those tumours which are
dependent on VEGF for their growth. It is further believed that
these compounds may be of interest in treating tumour states
associated with both VEGF and EGF, especially where a patient is
suffering from a condition in which tumours are present which are
dependent on both VEGF and EGF for their growth.
[0008] According to one aspect of the present invention there is
provided a quinazoline derivative of the formula I: ##STR2##
wherein: m is an integer from 1 to 3; R.sup.1 represents halogeno
or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected
from one of the following three groups: 1) C.sub.1-5alkylR.sup.3
(wherein R.sup.3 is piperidin-4-yl which may bear one or two
substituents selected from hydroxy, halogeno, C.sub.1-4alkyl,
C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2)
C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined
hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as
defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl
group may bear one or more substituents selected from hydroxy,
halogeno and amino; or a salt thereof or a prodrug thereof.
Preferably m is 2. Preferably the phenyl group bearing
(R.sup.1).sub.m is selected from 2-fluoro-4-methylphenyl,
4-chloro-2,6-difluorophenyl, 4-bromo-2,6-difluorophenyl,
4-chloro-2-fluorophenyl group and 4-bromo-2-fluorophenyl. More
preferably the phenyl group bearing (R.sup.1).sub.m is selected
from 4-chloro-2-fluorophenyl and 4-bromo-2-fluorophenyl. Most
preferably the phenyl group bearing (R.sup.1).sub.m is
4-bromo-2-fluorophenyl. Preferably R.sup.2 is C.sub.1-5alkylR.sup.3
(wherein R.sup.3 is as defined hereinbefore). More preferably
R.sup.2 is C.sub.1-3alkylR.sup.3(wherein R.sup.3 is as defined
hereinbefore). Particularly R.sup.2 is piperidin-4-ylmethyl in
which the piperidine ring may bear one or two substituents as
defined hereinbefore. More particularly R.sup.2 is
piperidin-4-ylmethyl in which the piperidine ring may bear one or
two substituents selected from C.sub.1-4alkyl. Especially R.sup.2
is 1-methylpiperidin-4-ylmethyl.
[0009] According to a further aspect of the present invention there
is provided a quinazoline derivative of the formula II: ##STR3##
wherein: ma is an integer from 1 to 3; R.sup.1a represents halogeno
or C.sub.1-3alkyl; X.sup.1a represents --O--; R.sup.2a is selected
from one of the following three groups: 1) C.sub.1-5-alkylR.sup.3
(wherein R.sup.3 is as defined hereinbefore); 2)
C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined
hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as
defined hereinbefore); or a salt thereof or a prodrug thereof.
Preferably ma is 2. Preferably the phenyl group bearing
(R.sup.1a).sub.ma is selected from 2-fluoro-4-methylphenyl,
4-chloro-2,6-difluorophenyl, 4-bromo-2,6-difluorophenyl,
4-chloro-2-fluorophenyl group and 4-bromo-2-fluorophenyl. More
preferably the phenyl group bearing (R.sup.1a).sub.ma is selected
from 4-chloro-2-fluorophenyl and 4-bromo-2-fluorophenyl. Most
preferably the phenyl group bearing (R.sup.1a).sub.ma is
4-bromo-2-fluorophenyl. Preferably R.sup.2a is
C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is as defined hereinbefore).
More preferably R.sup.2a is C.sub.1-3alkylR.sup.3(wherein R.sup.3
is as defined hereinbefore). Particularly R.sup.2a is
piperidin-4-ylmethyl in which the piperidine ring may bear one or
two substituents as defined hereinbefore. More particularly
R.sup.2a is piperidin-4-ylmethyl in which the piperidine ring may
bear one or two substituents selected from C.sub.1-4alkyl.
Especially R.sup.2a is 1-methylpiperidin-4-ylmethyl. Preferred
compounds of the present invention include: [0010]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline, [0011]
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline, [0012]
4-(4-bromo-2-fluoroanilino)methoxy-7-(1-methylpiperidin-4-ylmethoxy)quina-
zoline, [0013]
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline, [0014]
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-methylpiperidin-4-ylmethoxy)q-
uinazoline, [0015]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoli-
ne, [0016]
4-(2-fluoro-4-methylanilino)-6-methoxy-7(-piperidin-4-ylmethoxy)quinazoli-
ne, [0017]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazolin-
e, [0018]
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quina-
zoline, and
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinaz-
oline, and salts thereof especially hydrochloride salts thereof.
More preferred compounds of the present invention include: [0019]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline, [0020]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline, [0021]
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline, [0022]
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethox-
y)quinazoline, [0023]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoli-
ne, [0024]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazolin-
e, [0025]
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quina-
zoline, and [0026]
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinaz-
oline, and salts thereof especially hydrochloride salts thereof.
Particularly preferred compounds of the present invention include:
[0027]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylm-
ethoxy)quinazoline, [0028]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline, [0029]
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline, and [0030]
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethox-
y)quinazoline, and salts thereof especially hydrochloride salts
thereof. More particularly preferred compounds of the present
invention include: [0031]
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl-
methoxy)quinazoline and [0032]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline, and salts thereof especially hydrochloride salts
thereof. An especially preferred compound of the present invention
is [0033]
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline and salts thereof especially hydrochloride salts
thereof.
[0034] For the avoidance of doubt it is to be understood that where
in this specification a group is qualified by `hereinbefore
defined` or `defined hereinbefore` the said group encompasses the
first occurring and broadest definition as well as each and all of
the preferred definitions for that group. And a similar convention
applies to `hereinafter defined` or `defined hereinafter`.
[0035] In this specification unless stated otherwise the term
"alkyl" includes both straight and branched chain alkyl groups but
references to individual alkyl groups such as "propyl" are specific
for the straight chain version only. An analogous convention
applies to other generic terms. Unless otherwise stated the term
"alkyl" advantageously refers to chains with 1-5 carbon atoms,
preferably 1-3 carbon atoms. The term "alkoxy" as used herein,
unless stated otherwise includes "alkyl"-O-- groups in which
"alkyl" is as hereinbefore defined. The term "aryl" as used herein
unless stated otherwise includes reference to a C.sub.6-10 aryl
group which may, if desired, carry one or more substituents
selected from halogeno, alkyl, alkoxy, nitro, trifluoromethyl and
cyano, (wherein alkyl and alkoxy are as hereinbefore defined). The
term "aryloxy" as used herein unless otherwise stated includes
"aryl"-O-groups in which "aryl" is as hereinbefore defined. The
term "sulphonyloxy" as used herein refers to alkylsulphonyloxy and
arylsulphonyloxy groups in which "alkyl" and "aryl" are as
hereinbefore defined. The term "alkanoyl" as used herein unless
otherwise stated includes formyl and alkylC.dbd.O groups in which
"alkyl" is as defined hereinbefore, for example C.sub.2alkanoyl is
ethanoyl and refers to CH.sub.3C.dbd.O, C.sub.1alkanoyl is formyl
and refers to CHO. In this specification unless stated otherwise
the term "alkenyl" includes both straight and branched chain
alkenyl groups but references to individual alkenyl groups such as
2-butenyl are specific for the straight chain version only. Unless
otherwise stated the term "alkenyl" advantageously refers to chains
with 2-5 carbon atoms, preferably 3-5 carbon atoms. In this
specification unless stated otherwise the term "alkynyl" includes
both straight and branched chain alkynyl groups but references to
individual alkynyl groups such as 2-butynyl are specific for the
straight chain version only. Unless otherwise stated the term
"alkynyl" advantageously refers to chains with 2-5 carbon atoms,
preferably 3-5 carbon atoms.
[0036] In formula I, as hereinbefore defined, hydrogen will be
present at positions 2, 5 and 8 of the quinazoline group.
[0037] Within the present invention it is to be understood that a
compound of the formula I or a salt thereof may exhibit the
phenomenon of tautomerism and that the formulae drawings within
this specification can represent only one of the possible
tautomeric forms. It is to be understood that the invention
encompasses any tautomeric form which inhibits VEGF receptor
tyrosine kinase activity and is not to be limited merely to any one
tautomeric form utilised within the formulae drawings.
[0038] It is also to be understood that certain compounds of the
formula I and salts thereof can exist in solvated as well as
unsolvated forms such as, for example, hydrated forms. It is to be
understood that the invention encompasses all such solvated forms
which inhibit VEGF receptor tyrosine kinase activity.
[0039] For the avoidance of any doubt, it is to be understood that
in a compound of the formula I when R.sup.2 is, for example, a
group of formula C.sub.2-5alkenylR.sup.3 it is the C.sub.2-5alkenyl
moiety which is bound to X.sup.1 and an analogous convention
applies to other groups. When R.sup.2 is a group
1-R.sup.3prop-1-en-3-yl it is the first carbon to which the group
R.sup.3 is attached and it is the third carbon which is linked to
X.sup.1, similarly when R.sup.2 is a group 2-R.sup.3pent-3-en-5-yl
it is the second carbon to which the group R.sup.3 is attached and
it is the fifth carbon which is linked to X.sup.1, and an analogous
convention applies to other groups.
[0040] Compounds of Formula I may be administered in the form of a
prodrug which is broken down in the human or animal body to give a
compound of the Formula I. Examples of prodrugs include in vivo
hydrolysable esters of a compound of the Formula I.
[0041] Various forms of prodrugs are known in the art. For examples
of such prodrug derivatives see:
a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and
Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et
al. (Academic Press, 1985);
b) A Textbook of Drug Design and Development, edited by
Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and
Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38
(1992);
d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77,
285 (1988); and
e) N. Kakeya, et al., Chem Pharm Bull, 32, 692 (1984).
[0042] An in vivo hydrolysable ester of a compound of Formula I
containing a hydroxy group includes inorganic esters such as
phosphate esters (including phosphoramidic cyclic esters) and
a-acyloxyalkyl ethers and related compounds which as a result of
the in vivo hydrolysis of the ester breakdown to give the parent
hydroxy group/s. Examples of a-acyloxyalkyl ethers include
acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of
in vivo hydrolysable ester forming groups for hydroxy include
alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and
phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters),
dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to
give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of
substituents on benzoyl include morpholino and piperazino linked
from a ring nitrogen atom via a methylene group to the 3- or
4-position of the benzoyl ring.
[0043] The present invention relates to the compounds of formula I
as hereinbefore defined as well as to the salts thereof. Salts for
use in pharmaceutical compositions will be pharmaceutically
acceptable salts, but other salts may be useful in the production
of the compounds of formula I and their pharmaceutically acceptable
salts. Pharmaceutically acceptable salts of the invention may, for
example, include acid addition salts of the compounds of formula I
as hereinbefore defined which are sufficiently basic to form such
salts. Such acid addition salts include for example salts with
inorganic or organic acids affording pharmaceutically acceptable
anions such as with hydrogen halides (especially hydrochloric or
hydrobromic acid of which hydrochloric acid is particularly
preferred) or with sulphuric or phosphoric acid, or with
trifluoroacetic, citric or maleic acid. In addition where the
compounds of formula I are sufficiently acidic, pharmaceutically
acceptable salts may be formed with an inorganic or organic base
which affords a pharmaceutically acceptable cation. Such salts with
inorganic or organic bases include for example an alkali metal
salt, such as a sodium or potassium salt, an alkaline earth metal
salt such as a calcium or magnesium salt, an ammonium salt or for
example a salt with methylamine, dimethylamine, trimethylamine,
piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0044] A compound of the formula I, or salt thereof, and other
compounds of the invention (as hereinafter defined) may be prepared
by any process known to be applicable to the preparation of
chemically-related compounds. Such processes include, for example,
those illustrated in European Patent Applications, Publication Nos.
0520722, 0566226, 0602851 and 0635498 and in International Patent
Applications Publication Nos. WO 97/22596, WO 97/30035, WO 97/32856
and WO 98/13354. Such processes, are provided as a further feature
of the invention and are as described hereinafter. Necessary
starting materials may be obtained by standard procedures of
organic chemistry. The preparation of such starting materials is
described within the accompanying non-limiting Examples.
Alternatively necessary starting materials are obtainable by
analogous procedures to those illustrated which are within the
ordinary skill of an organic chemist.
[0045] Thus the following processes (a) to (d) and (i) to (iv)
constitute further features of the present invention.
Synthesis of Compounds of Formula I
[0046] (a) Compounds of the formula I and salts thereof may be
prepared by the reaction of a compound of the formula III: ##STR4##
(wherein R.sup.2 and X.sup.1 are as defined hereinbefore and
L.sup.1 is a displaceable moiety), with a compound of the formula
IV: ##STR5## (wherein R.sup.1 and m are as defined hereinbefore)
whereby to obtain compounds of the formula I and salts thereof. A
convenient displaceable moiety L.sup.1 is, for example, a halogeno,
alkoxy (preferably C.sub.1-4alkoxy), aryloxy or sulphonyloxy group,
for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy
or toluene-4-sulphonyloxy group.
[0047] The reaction is advantageously effected in the presence of
either an acid or a base. Such an acid is, for example, an
anhydrous inorganic acid such as hydrogen chloride. Such a base is,
for example, an organic amine base such as, for example, pyridine,
2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine,
morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene,
or for example, an alkali metal or alkaline earth metal carbonate
or hydroxide, for example sodium carbonate, potassium carbonate,
calcium carbonate, sodium hydroxide or potassium hydroxide.
Alternatively such a base is, for example, an alkali metal hydride,
for example sodium hydride, or an alkali metal or alkaline earth
metal amide, for example sodium amide or sodium
bis(trimethylsilyl)amide. The reaction is preferably effected in
the presence of an inert solvent or diluent, for example an alkanol
or ester such as methanol, ethanol, 2-propanol or ethyl acetate, a
halogenated solvent such as methylene chloride, trichloromethane or
carbon tetrachloride, an ether such as tetrahydrofuran or
1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a
dipolar aprotic solvent such as N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidin-2-one or
dimethylsulphoxide. The reaction is conveniently effected at a
temperature in the range, for example, 10 to 150.degree. C.,
preferably in the range 20 to 80.degree. C.
[0048] The compound of the invention may be obtained from this
process in the form of the free base or alternatively it may be
obtained in the form of a salt with the acid of the formula
H-L.sup.1 wherein L.sup.1 has the meaning defined hereinbefore.
When it is desired to obtain the free base from the salt, the salt
may be treated with a base as defined hereinbefore using a
conventional procedure.
[0049] (b) Compounds of the formula I and salts thereof may be
prepared by the reaction, conveniently in the presence of a base as
defined hereinbefore, of a compound of the formula V: ##STR6##
(wherein m, X.sup.1 and R.sup.1 are as hereinbefore defined) with a
compound of formula VI: R.sup.2-L.sup.1 (VI) (wherein R.sup.2 and
L.sup.1 are as hereinbefore defined); L.sup.1 is a displaceable
moiety for example a halogeno or sulphonyloxy group such as a bromo
or methanesulphonyloxy group. Conveniently L.sup.1 is a group
O--.sup.+P(Y).sub.3 (wherein Y is butyl or phenyl) and in such
cases the compound of formula VI is conveniently formed in situ.
The reaction is preferably effected in the presence of a base (as
defined hereinbefore in process (a)) and advantageously in the
presence of an inert solvent or diluent (as defined hereinbefore in
process (a)), advantageously at a temperature in the range, for
example 10 to 150.degree. C., conveniently at about 50.degree.
C.
[0050] (c) Compounds of the formula I and salts thereof may be
prepared by the reaction of a compound of the formula VII: ##STR7##
with a compound of the formula VIII: R.sup.2--X.sup.1--H (VIII)
(wherein L.sup.1, R.sup.1, R.sup.2, m and X.sup.1 are all as
hereinbefore defined). The reaction may conveniently be effected in
the presence of a base (as defined hereinbefore in process (a)) and
advantageously in the presence of an inert solvent or diluent (as
defined hereinbefore in process (a)), advantageously at a
temperature in the range, for example 10 to 150.degree. C.,
conveniently at about 100.degree. C.
[0051] (d) Compounds of the formula I and salts thereof may be
prepared by the deprotection of a compound of the formula IX:
##STR8## wherein R.sup.1, m and X.sup.1 are all as hereinbefore
defined, and R.sup.4 represents a protected R.sup.2 group wherein
R.sup.2 is as defined hereinbefore but additionally bears one or
more protecting groups P.sup.2. The choice of protecting group
P.sup.2 is within the standard knowledge of an organic chemist for
example those included in standard texts such as "Protective Groups
in Organic Synthesis" T. W. Greene and R. G. M. Wuts, 2nd Ed. Wiley
1991. Preferably P.sup.2 is a protecting group such as a carbamate
(alkoxycarbonyl) (such as, for example, tert-butoxycarbonyl,
tert-amyloxycarbonyl, cyclobutoxycarbaonyl, propoxycarbonyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl,
allyloxycarbonyl or benzyloxycarbonyl). More preferably P.sup.2 is
tert-butoxycarbonyl. The reaction is preferably effected in the
presence of an acid. Such an acid is, for example, an inorganic
acid such as hydrogen chloride, hydrogen bromide or an organic acid
such as trifluoroacetic acid, trifluoromethane sulphonic acid. The
reaction may be effected in the presence of an inert solvent such
as methylene chloride, trichloromethane and in the presence of a
trace of water. The reaction is conveniently effected at a
temperature in the range, for example, 10-100.degree. C.,
preferably in the range 20-80.degree. C. Synthesis of
Intermediates
[0052] (i) The compounds of formula III and salts thereof in which
L.sup.1 is halogeno may for example be prepared by halogenating a
compound of the formula X: ##STR9## (wherein R.sup.2 and X.sup.1
are as hereinbefore defined).
[0053] Convenient halogenating agents include inorganic acid
halides, for example thionyl chloride, phosphorus(III)chloride,
phosphorus(V)oxychloride and phosphorus(V)chloride. The
halogenation reaction is conveniently effected in the presence of
an inert solvent or diluent such as for example a halogenated
solvent such as methylene chloride, trichloromethane or carbon
tetrachloride, or an aromatic hydrocarbonsolvent such as benzene or
toluene. The reaction is conveniently effected at a temperature in
the range, for example 10 to 150.degree. C., preferably in the
range 40 to 100.degree. C.
[0054] The compounds of formula X and salts thereof may for example
be prepared by reacting a compound of the formula XI: ##STR10##
(wherein L.sup.1 is as hereinbefore defined) with a compound of the
formula VIII as hereinbefore defined. The reaction may conveniently
be effected in the presence of a base (as defined hereinbefore in
process (a)) and advantageously in the presence of an inert solvent
or diluent (as defined hereinbefore in process (a)), advantageously
at a temperature in the range, for example 10 to 150.degree. C.,
conveniently at about 100.degree. C.
[0055] The compounds of formula X and salts thereof may also be
prepared by cyclising a compound of the formula XII: ##STR11##
(wherein R.sup.2 and X.sup.1, are as hereinbefore defined, and
A.sup.1 is an hydroxy, alkoxy (preferably C.sub.1-4alkoxy) or amino
group) whereby to form a compound of formula X or salt thereof. The
cyclisation may be effected by reacting a compound of the formula
XII, where A.sup.1 is an hydroxy or alkoxy group, with formamide or
an equivalent thereof effective to cause cyclisation whereby a
compound of formula X or salt thereof is obtained, such as
[3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride.
The cyclisation is conveniently effected in the presence of
formamide as solvent or in the presence of an inert solvent or
diluent such as an ether for example 1,4-dioxan. The cyclisation is
conveniently effected at an elevated temperature, preferably in the
range 80 to 200.degree. C. The compounds of formula X may also be
prepared by cyclising a compound of the formula XII, where A.sup.1
is an amino group, with formic acid or an equivalent thereof
effective to cause cyclisation whereby a compound of formula X or
salt thereof is obtained. Equivalents of formic acid effective to
cause cyclisation include for example a tri-C.sub.1-4alkoxymethane,
for example triethoxymethane and trimethoxymethane. The cyclisation
is conveniently effected in the presence of a catalytic amount of
an anhydrous acid, such as a sulphonic acid for example
p-toluenesulphonic acid, and in the presence of an inert solvent or
diluent such as for example a halogenated solvent such as methylene
chloride, trichloromethane or carbon tetrachloride, an ether such
as diethyl ether or tetrahydrofuran, or an aromatic hydrocarbon
solvent such as toluene. The cyclisation is conveniently effected
at a temperature in the range, for example 10 to 100.degree. C.,
preferably in the range 20 to 50.degree. C.
[0056] Compounds of formula XII and salts thereof may for example
be prepared by the reduction of the nitro group in a compound of
the formula XIII: ##STR12## (wherein R.sup.2, X.sup.1 and A.sup.1
are as hereinbefore defined) to yield a compound of formula XII as
hereinbefore defined. The reduction of the nitro group may
conveniently be effected by any of the procedures known for such a
transformation. The reduction may be carried out, for example, by
the hydrogenation of a solution of the nitro compound in the
presence of an inert solvent or diluent as defined hereinbefore in
the presence of a metal effective to catalyse hydrogenation
reactions such as palladium or platinum. A further reducing agent
is, for example, an activated metal such as activated iron
(produced for example by washing iron powder with a dilute solution
of an acid such as hydrochloric acid). Thus, for example, the
reduction may be effected by heating the nitro compound and the
activated metal in the presence of a solvent or diluent such as a
mixture of water and alcohol, for example methanol or ethanol, to a
temperature in the range, for example 50 to 150.degree. C.,
conveniently at about 70.degree. C.
[0057] Compounds of the formula XIII and salts thereof may for
example be prepared by the reaction of a compound of the formula
XIV: ##STR13## (wherein L.sup.1 and A.sup.1 are as hereinbefore
defined) with a compound of the formula VIII as hereinbefore
defined to give a compound of the formula XIII. The reaction of the
compounds of formulae XIV and VIII is conveniently effected under
conditions as described for process (c) hereinbefore.
[0058] Compounds of formula XIII and salts thereof, may for example
also be prepared by the reaction of a compound of the formula XV:
##STR14## (wherein X.sup.1 and A.sup.1 are as hereinbefore defined)
with a compound of the formula VI as hereinbefore defined to yield
a compound of formula XIII as hereinbefore defined. The reaction of
the compounds of formulae XV and VI is conveniently effected under
conditions as described for process (b) hereinbefore.
[0059] The compounds of formula III and salts thereof may also be
prepared for example by reacting a compound of the formula XVI:
##STR15## (wherein X.sup.1 is as hereinbefore defined and L.sup.2
represents a displaceable protecting moiety) with a compound of the
formula VI as hereinbefore defined, whereby to obtain a compound of
formula III in which L.sup.1 is represented by L.sup.2.
[0060] A compound of formula XVI is conveniently used in which
L.sup.2 represents a phenoxy group which may if desired carry up to
5 substituents, preferably up to 2 substituents, selected from
halogeno, nitro and cyano. The reaction may be conveniently
effected under conditions as described for process (b)
hereinbefore.
[0061] The compounds of formula XVI and salts thereof as
hereinbefore defined may for example be prepared by deprotecting a
compound of the formula XVII: ##STR16## (wherein X.sup.1 and
L.sup.2 are as hereinbefore defined and P.sup.1 represents a
phenolic hydroxy protecting group). The choice of phenolic hydroxy
protecting group P.sup.1 is within the standard knowledge of an
organic chemist, for example those included in standard texts such
as "Protective Groups in Organic Synthesis" T. W. Greene and R. G.
M. Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl,
methoxymethyl, allyl and benzyl and benzyl substituted with up to
two substituents selected from C.sub.1-4alkoxy and nitro), silyl
ethers (for example, t-butyldiphenylsilyl and
t-butyldimethylsilyl), esters (for example, acetate and benzoate)
and carbonates (for example, methyl and benzyl and benzyl
substituted with up to two substituents selected from
C.sub.1-4alkoxy and nitro). Deprotection may be effected by
techniques well known in the literature, for example where P.sup.1
represents a benzyl group deprotection may be effected by
hydrogenolysis or by treatment with trifluoroacetic acid.
[0062] The removal of such a phenolic hydroxy protecting group may
be effected by any of the procedures known for such a
transformation, including those reaction conditions indicated in
standard texts such as that indicated hereinbefore, or by a related
procedure. The reaction conditions preferably being such that the
hydroxy derivative is produced without unwanted reactions at other
sites within the starting or product compounds. For example, where
the protecting group P.sup.1 is acetate, the transformation may
conveniently be effected by treatment of the quinazoline derivative
with a base as defined hereinbefore and including ammonia, and its
mono and di-alkylated derivatives, preferably in the presence of a
protic solvent or co-solvent such as water or an alcohol, for
example methanol or ethanol. Such a reaction can be effected in the
presence of an additional inert solvent or diluent as defined
hereinbefore and at a temperature in the range 0 to 50.degree. C.,
conveniently at about 20.degree. C.
[0063] One compound of formula III may if desired be converted into
another compound of formula III in which the moiety L.sup.1 is
different. Thus for example a compound of formula III in which
L.sup.1 is other than halogeno, for example optionally substituted
phenoxy, may be converted to a compound of formula III in which
L.sup.1 is halogeno by hydrolysis of a compound of formula II (in
which L.sup.1 is other than halogeno) to yield a compound of
formula X as hereinbefore defined, followed by introduction of
halide to the compound of formula X, thus obtained as hereinbefore
defined, to yield a compound of formula III in which L.sup.1
represents halogeno. (ii) Compounds of the formula V as
hereinbefore defined and salts thereof may be made by deprotecting
the compound of formula XVIII: ##STR17## (wherein R.sup.1, P.sup.1,
X.sup.1 and m are as hereinbefore defined) by a process for example
as described in (i) above.
[0064] Compounds of the formula XVIII and salts thereof may be made
by reacting compounds of the formulae XVII and IV as hereinbefore
defined, under the conditions described in (a) hereinbefore, to
give a compound of the formula XVIII or salt thereof.
[0065] (iii) Compounds of the formula VII and salts thereof as
hereinbefore defined may be made by reacting a compound of the
formula XIX: ##STR18## (wherein L.sup.1 is as hereinbefore defined,
and L.sup.1 in the 4- and 7-positions may be the same or different)
with a compound of formula IV as hereinbefore defined, the reaction
for example being effected by a process as described in (a)
above.
[0066] (iv) A compound of the formula IX may be prepared by the
reaction of a compound of the formula V as defined hereinbefore
with a compound of the formula XX: R.sup.4-L.sup.1 (XX) wherein
R.sup.4 and L.sup.1 are as defined hereinbefore under the
conditions described in (b) hereinbefore to give a compound of the
formula IX or salt thereof. The reaction is preferably effected in
the presence of a base (as defined hereinbefore in process (a)) and
advantageously in the presence of an inert solvent or diluent (as
defined hereinbefore in process (a)), advantageously at a
temperature in the range, for example 10 to 150.degree. C.,
conveniently in the range 20-50.degree. C.
[0067] When a pharmaceutically acceptable salt of a compound of the
formula I is required, it may be obtained, for example, by reaction
of said compound with, for example, an acid using a conventional
procedure, the acid having a pharmaceutically acceptable anion, or
it may be obtained by reaction of said compound with a base by a
conventional procedure.
[0068] The identification of compounds which potently inhibit the
tyrosine kinase activity associated with the VEGF receptors such as
Flt and/or KDR and which inhibit angiogenesis and/or increased
vascular permeability is desirable and is the subject of the
present invention. These properties may be assessed, for example,
using one or more of the procedures set out below:
(a) In Vitro Receptor Tyrosine Kinase Inhibition Test
[0069] This assay determines the ability of a test compound to
inhibit tyrosine kinase activity. DNA encoding VEGF or epidermal
growth factor (EGF) receptor cytoplasmic domains may be obtained by
total gene synthesis (Edwards M, International Biotechnology Lab
5(3), 19-25, 1987) or by cloning. These may then be expressed in a
suitable expression system to obtain polypeptide with tyrosine
kinase activity. For example VEGF and EGF receptor cytoplasmic
domains, which were obtained by expression of recombinant protein
in insect cells, were found to display intrinsic tyrosine kinase
activity. In the case of the VEGF receptor Flt (Genbank accession
number X51602), a 1.7 kb DNA fragment encoding most of the
cytoplasmic domain, commencing with methionine 783 and including
the termination codon, described by Shibuya et al (Oncogene, 1990,
5: 519-524), was isolated from cDNA and cloned into a baculovirus
transplacement vector (for example pAcYM1 (see The Baculovirus
Expression System: A Laboratory Guide, L. A. King and R. D. Possee,
Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from
Invitrogen Corporation)). This recombinant construct was
co-transfected into insect cells (for example Spodoptera frugiperda
21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare
recombinant baculovirus. (Details of the methods for the assembly
of recombinant DNA molecules and the preparation and use of
recombinant baculovirus can be found in standard texts for example
Sambrook et al, 1989, Molecular cloning--A Laboratory Manual, 2nd
edition, Cold Spring Harbour Laboratory Press and O'Reilly et al,
1992, Baculovirus Expression Vectors--A Laboratory Manual, W.H.
Freeman and Co, New York). For other tyrosine kinases for use in
assays, cytoplasmic fragments starting from methionine 806 (KDR,
Genbank accession number L04947) and methionine 668 (EGF receptor,
Genbank accession number X00588) may be cloned and expressed in a
similar manner.
[0070] For expression of cFlt tyrosine kinase activity, Sf21 cells
were infected with plaque-pure cFlt recombinant virus at a
multiplicity of infection of 3 and harvested 48 hours later.
Harvested cells were washed with ice cold phosphate buffered saline
solution (PBS) (10 nM sodium phosphate pH7.4, 138 mM sodium
chloride, 2.7 mM potassium chloride) then resuspended in ice cold
HNTG/PMSF (20 mM Hepes pH7.5, 150 mM sodium chloride, 10% v/v
glycerol, 1% v/v Triton X100, 1.5 mM magnesium chloride, 1 mM
ethylene glycol-bis(.beta.aminoethyl ether) N,N,N',5N'-tetraacetic
acid (EGTA), 1 mM PMSF (phenylmethylsulphonyl fluoride); the PMSF
is added just before use from a freshly-prepared 100 mM solution in
methanol) using 1 ml HNTG/PMSF per 10 million cells. The suspension
was centrifuged for 10 minutes at 13,000 rpm at 4.degree. C., the
supernatant (enzyme stock) was removed and stored in aliquots at
-70.degree. C. Each new batch of stock enzyme was titrated in the
assay by dilution with enzyme diluent (100 mM Hepes pH 7.4, 0.2 mM
sodium orthovanadate, 0.1% v/v Triton X100, 0.2 mM dithiothreitol).
For a typical batch, stock enzyme is diluted 1 in 2000 with enzyme
diluent and 50 .mu.l of dilute enzyme is used for each assay
well.
[0071] A stock of substrate solution was prepared from a random
copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr)
6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at -20.degree.
C. and diluted 1 in 500 with PBS for plate coating.
[0072] On the day before the assay 100 .mu.l of diluted substrate
solution was dispensed into all wells of assay plates (Nunc
maxisorp 96-well immunoplates) which were sealed and left overnight
at 4.degree. C.
[0073] On the day of the assay the substrate solution was discarded
and the assay plate wells were washed once with PBST (PBS
containing 0.05% v/v Tween 20) and once with 50 mM Hepes pH7.4.
[0074] Test compounds were diluted with 10% dimethylsulphoxide
(DMSO) and 25 .mu.l of diluted compound was transferred to wells in
the washed assay plates. "Total" control wells contained 10% DMSO
instead of compound. Twenty five microlitres of 40 mM
manganese(II)chloride containing 8 .mu.M adenosine-5'-triphosphate
(ATP) was added to all test wells except "blank" control wells
which contained manganese(II) chloride without ATP. To start the
reactions 50 .mu.l of freshly diluted enzyme was added to each well
and the plates were incubated at room temperature for 20 minutes.
The liquid was then discarded and the wells were washed twice with
PBST. One hundred microlitres of mouse IgG anti-phosphotyrosine
antibody (Upstate Biotechnology Inc. product 05-321), diluted 1 in
6000 with PBST containing 0.5% w/v bovine serum albumin (BSA), was
added to each well and the plates were incubated for 1 hour at room
temperature before discarding the liquid and washing the wells
twice with PBST. One hundred microlitres of horse radish peroxidase
(HRP)-linked sheep anti-mouse Ig antibody (Amersham product NXA
931), diluted 1 in 500 with PBST containing 0.5% w/v BSA, was added
and the plates were incubated for 1 hour at room temperature before
discarding the liquid and washing the wells twice with PBST. One
hundred microlitres of
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS)
solution, freshly prepared using one 50 mg ABTS tablet (Boehringer
1204 521) in 50 ml freshly prepared 50 mM phosphate-citrate buffer
pH5.0+0.03% sodium perborate (made with 1 phosphate citrate buffer
with sodium perborate (PCSB) capsule (Sigma P4922) per 100 ml
distilled water), was added to each well. Plates were then
incubated for 20-60 minutes at room temperature until the optical
density value of the "total" control wells, measured at 405 nm
using a plate reading spectrophotometer, was approximately 1.0.
"Blank" (no ATP) and "total" (no compound) control values were used
to determine the dilution range of test compound which gave 50%
inhibition of enzyme activity.
(b) In Vitro HUVEC Proliferation Assay
[0075] This assay determines the ability of a test compound to
inhibit the growth factor-stimulated proliferation of human
umbilical vein endothelial cells (HUVEC).
[0076] HUVEC cells were isolated in MCDB 131 (Gibco BRL)+7.5% v/v
foetal calf serum (FCS) and were plated out (at passage 2 to 8), in
MCDB 131+2% v/v FCS+3 .mu.g/ml heparin+1 .mu.g/ml hydrocortisone,
at a concentration of 1000 cells/well in 96 well plates. After a
minimum of 4 hours they were dosed with the appropriate growth
factor (i.e. VEGF 3 ng/ml, EGF 3 ng/ml or b-FGF 0.3 ng/ml) and
compound. The cultures were then incubated for 4 days at 37.degree.
C. with 7.5% carbon dioxide. On day 4 the cultures were pulsed with
1 .mu.Ci/well of tritiated-thymidine (Amersham product TRA 61) and
incubated for 4 hours. The cells were harvested using a 96-well
plate harvester (Tomtek) and then assayed for incorporation of
tritium with a Beta plate counter. Incorporation of radioactivity
into cells, expressed as cpm, was used to measure inhibition of
growth factor-stimulated cell proliferation by compounds.
(c) In Vivo Solid Tumour Disease Model
This test measures the capacity of compounds to inhibit solid
tumour growth.
[0077] CaLu-6 tumour xenografts were established in the flank of
female athymic Swiss nu/nu mice, by subcutaneous injection of
1.times.10.sup.6 CaLu-6 cells/mouse in 100 .mu.l of a 50% (v/v)
solution of Matrigel in serum free culture medium. Ten days after
cellular implant, mice were allocated to groups of 8-10, so as to
achieve comparable group mean volumes. Tumours were measured using
vernier calipers and volumes were calculated as: (1.times.w).times.
(1.times.w).times.(.pi./6), where 1 is the longest diameter and w
the diameter perpendicular to the longest diameter. Test compounds
were administered orally once daily for a minimum of 21 days, and
control animals received compound diluent. Tumours were measured
twice weekly. The level of growth inhibition was calculated by
comparison of the mean tumour volume of the control group versus
the treatment group, and statistical significance determined using
a Students' t-test and/or a Mann-Whitney Rank Sum Test. The
inhibitory effect of compound treatment was considered significant
when p<0.05.
[0078] The toxicological profile of compounds of the present
invention may be assessed, for example using a rat 14 day study as
described hereinafter.
(d) 14 Day Toxicity Test in Rat
[0079] This test measures the activity of compounds in increasing
the zone of hypertrophy in the femoral epiphyseal growth plates of
the distal femur and proximal tibia, and allows assessment of
histopathological changes in other tissues.
[0080] Angiogenesis is an essential event in endochondral
ossification during long bone elongation, and vascular invasion of
the growth plate has been suggested to depend upon VEGF production
by hypertrophic chondrocytes. Expansion of the hypertrophic
chondrocyte zone and inhibition of angiogenesis has been
demonstrated following treatment with agents which specifically
sequester VEGF, such as, for example, (i) a soluble VEGF receptor
chimeric protein (Flt-(1-3)-IgG) in mice (Gerber, H-P., Vu, T. H.,
Ryan, A. M., Kowalski, J., Werb, Z. and Ferrara, N. VEGF couples
hypertrophic cartilage remodelling, ossification and angiogenesis
during endochondral bone formation, Nature Med., 5: 623-628, 1999)
and (ii) a recombinant humanised anti-VEGF monoclonal IgG1 antibody
in cynomologus monkey (Ryan, A. M., Eppler, D. B., Hagler, K. E.,
Bruner, R. H., Thomford, P. J., Hall, R. L., Shopp, G. M. and
O'Niell, C. A. Preclinical Safety Evaluation of rhuMAbVEGF, an
antiangiogenic humanised monoclonal antibody, Tox. Path., 27:
78-86, 1999).
[0081] An inhibitor of VEGF receptor tyrosine kinase activity
should therefore also inhibit vascular invasion of cartilage, and
increase the zone of hypertrophy in the femoral epiphyseal growth
plates of the distal femur and proximal tibia in growing
animals.
[0082] Compounds were initially formulated by suspension in a 1%
(v/v) solution of polyoxyethylene (20) sorbitan mono-oleate in
deionised water, by ball-milling at 4.degree. C. overnight (at
least 15 hours). Compounds were re-suspended by agitation
immediately prior to dosing. Young Alderley Park rats (Wistar
derived, 135-150 g in weight, 4 to 8 weeks of age, 5-6 per group)
were dosed once-daily by oral gavage for 14 consecutive days with
compound (at 0.25 ml/100 g body weight) or vehicle. On day 15
animals were humanely terminated using a rising concentration of
carbon dioxide, and a post-mortem performed. A range of tissues,
which included femoro-tibial joints, were collected and processed
by standard histological techniques to produce paraffin wax
sections. Histological sections were stained with haematoxylin and
eosin and examined by light microscopy for histopathology. The
femoral epiphyseal growth plate areas of the distal femur and
proximal tibia were measured in sections of femur and tibia using
morphometric image analysis. The increase in the zone of
hypertrophy was determined by comparison of the mean epiphyseal
growth plate area of the control group versus the treatment group,
and statistical significance determined using a one-tailed
Students' t-test. The inhibitory effect of compound treatment was
considered significant when p<0.05.
[0083] Although the pharmacological properties of the compounds of
Formula I vary with structural change, in general, activity
possessed by compounds of the Formula I, may be demonstrated at the
following concentrations or doses in one or more of the above tests
(a), (b), (c) and (d):
[0084] Test (a):--IC.sub.50 in the range, for example, <5
.mu.M;
[0085] Test (b):--IC.sub.50 in the range, for example, 0.001-5
.mu.M;
[0086] Test (c):--activity in the range, for example, 0.1-100
mg/kg;
[0087] Test (d):--activity in the range, for example, 0.1-100
mg/kg.
[0088] According to one aspect of the present invention compounds
of Formula I, assessed in the 14 day toxicity test in rat, have a
beneficial toxicological profile over other compounds within the
scope of International Patent Application Publication No. WO
98/13354.
[0089] According to another aspect of the present invention
compounds of Formula I, assessed in the 14 day toxicity test in
rat, have a beneficial toxicological profile over other compounds
within the scope of International Patent Application Publication
No. WO 97/30035.
[0090] Although the pharmacological properties of the compounds of
Formula I vary with structural change and between species, at doses
in the rat, preferably at doses less than or equal to 150 mg/kg,
more preferably at doses less than or equal to 100 mg/kg,
especially at doses less than or equal to 50 mg/kg, compounds of
Formula I which produce a statistically significant increase in the
femoral epiphyseal growth plate area of the distal femur and/or
proximal tibia, produce no unacceptable histopathological changes
in other tissues in tests (d) that we have conducted.
[0091] Thus by way of example, the compound
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline, (Example 2), tested according to (a), (b), (c) and (d)
above gave the following results:
(a)--Flt.sub.50 IC, of 1.6 .mu.M
[0092] KDR--IC.sub.50 of 0.04 .mu.M
[0093] EGFR--IC.sub.50 of 0.5 .mu.M
(b) VEGF--IC.sub.50 of 0.06 .mu.M
[0094] EGF--IC.sub..dbd.s of 0.17 .mu.M
[0095] Basal--IC.sub.50 of >3 .mu.M
(c) 78% inhibition of tumour growth at 50 mg/kg; p<0.001
(Mann-Whitney Rank Sum Test);
(d) 75% increase in epiphyseal growth plate hypertrophy at 100
mg/kg/day in female rats; p<0.001 (one-tailed Students'
t-test).
[0096] According to a further aspect of the invention there is
provided a pharmaceutical composition which comprises a compound of
the formula I as defined hereinbefore or a pharmaceutically
acceptable salt thereof, in association with a pharmaceutically
acceptable excipient or carrier.
[0097] The composition may be in a form suitable for oral
administration, (for example as tablets, lozenges, hard or soft
capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for administration by
inhalation (for example as a finely divided powder or a liquid
aerosol), for administration by insufflation (for example as a
finely divided powder), for parenteral injection (for example as a
sterile solution, suspension or emulsion for intravenous,
subcutaneous, intramuscular, intravascular or infusion dosing), for
topical administration (for example as creams, ointments, gels, or
aqueous or oily solutions or suspensions), or for rectal
administration (for example as a suppository). In general the above
compositions may be prepared in a conventional manner using
conventional excipients.
[0098] The compositions of the present invention are advantageously
presented in unit dosage form. The compound will normally be
administered to a warm-blooded animal at a unit dose within the
range 5-5000 mg per square metre body area of the animal, i.e.
approximately 0.1-100 mg/kg. A unit dose in the range, for example,
1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally
provides a therapeutically-effective dose. A unit dose form such as
a tablet or capsule will usually contain, for example 1-250 mg of
active ingredient.
[0099] According to a further aspect of the present invention there
is provided a compound of the formula I or a pharmaceutically
acceptable salt thereof as defined hereinbefore for use in a method
of treatment of the human or animal body by therapy.
[0100] We have found that compounds of the present invention
inhibit VEGF receptor tyrosine kinase activity and are therefore of
interest for their antiangiogenic effects and/or their ability to
cause a reduction in vascular permeability.
[0101] A further feature of the present invention is a compound of
formula I, or a pharmaceutically acceptable salt thereof, for use
as a medicament, conveniently a compound of formula I, or a
pharmaceutically acceptable salt thereof, for use as a medicament
for producing an antiangiogenic and/or vascular permeability
reducing effect in a warm-blooded animal such as a human being.
[0102] Thus according to a further aspect of the invention there is
provided the use of a compound of the formula I, or a
pharmaceutically acceptable salt thereof in the manufacture of a
medicament for use in the production of an antiangiogenic and/or
vascular permeability reducing effect in a warm-blooded animal such
as a human being.
[0103] According to a further feature of the invention there is
provided a method for producing an antiangiogenic and/or vascular
permeability reducing effect in a warm-blooded animal, such as a
human being, in need of such treatment which comprises
administering to said animal an effective amount of a compound of
formula I or a pharmaceutically acceptable salt thereof as defined
hereinbefore.
[0104] As stated above the size of the dose required for the
therapeutic or prophylactic treatment of a particular disease state
will necessarily be varied depending on the host treated, the route
of administration and the severity of the illness being treated.
Preferably a daily doses in the range of 1-50 mg/kg is employed.
However the daily dose will necessarily be varied depending upon
the host treated, the particular route of administration, and the
severity of the illness being treated. Accordingly the optimum
dosage may be determined by the practitioner who is treating any
particular patient.
[0105] The antiangiogenic and/or vascular permeability reducing
treatment defined hereinbefore may be applied as a sole therapy or
may involve, in addition to a compound of the invention, one or
more other substances and/or treatments. Such conjoint treatment
may be achieved by way of the simultaneous, sequential or separate
administration of the individual components of the treatment. In
the field of medical oncology it is normal practice to use a
combination of different forms of treatment to treat each patient
with cancer. In medical oncology the other component(s) of such
conjoint treatment in addition to the antiangiogenic and/or
vascular permeability reducing treatment defined hereinbefore may
be surgery, radiotherapy or chemotherapy. Such chemotherapy may
cover five main categories of therapeutic agent:
[0106] (i) other antiangiogenic agents that work by different
mechanisms from those defined hereinbefore (for example linomide,
inhibitors of integrin .alpha.v.beta.3 function, angiostatin,
endostatin, razoxin, thalidomide) and including vascular targeting
agents (for example combretastatin phosphate and the vascular
damaging agents described in International Patent Application
Publication No. WO 99/02166 the entire disclosure of which document
is incorporated herein by reference, (for example
N-acetylcolchinol-O-phosphate));
[0107] (ii) cytostatic agents such as antioestrogens (for example
tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene),
progestogens (for example megestrol acetate), aromatase inhibitors
(for example anastrozole, letrazole, vorazole, exemestane),
antiprogestogens, antiandrogens (for example flutamide, nilutamide,
bicalutamide, cyproterone acetate), LHRH agonists and antagonists
(for example goserelin acetate, luprolide, abarelix), inhibitors of
testosterone 5.alpha.-dihydroreductase (for example finasteride),
anti-invasion agents (for example metalloproteinase inhibitors like
marimastat and inhibitors of urokinase plasminogen activator
receptor function) and inhibitors of growth factor function, (such
growth factors include for example platelet derived growth factor
and hepatocyte growth factor such inhibitors include growth factor
antibodies, growth factor receptor antibodies, tyrosine kinase
inhibitors and serine/threonine kinase inhibitors);
[0108] (iii) biological response modifiers (for example
interferon);
[0109] (iv) antibodies (for example edrecolomab); and
[0110] (v) antiproliferative/antineoplastic drugs and combinations
thereof, as used in medical oncology, such as antimetabolites (for
example antifolates like methotrexate, fluoropyrimidines like
5-fluorouracil, purine and adenosine analogues, cytosine
arabinoside); antitumour antibiotics (for example anthracyclines
like doxorubicin, daunomycin, epirubicin and idarubicin,
mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for
example cisplatin, carboplatin); alkylating agents (for example
nitrogen mustard, melphalan, chlorambucil, busulphan,
cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic
agents (for example vinca alkaloids like vincristine and taxoids
like taxol, taxotere); enzymes (for example asparaginase);
thymidylate synthase inhibitors (for example raltitrexed);
topoisomerase inhibitors (for example epipodophyllotoxins like
etoposide and teniposide, amsacrine, topotecan, irinotecan).
[0111] For example such conjoint treatment may be achieved by way
of the simultaneous, sequential or separate administration of a
compound of formula I as defined hereinbefore such as
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline or a salt thereof especially a hydrochloride salt
thereof, and a vascular targeting agent described in WO 99/02166
such as N-acetylcolchinol-O-phosphate (Example 1 of WO
99/02166).
[0112] As stated above the compounds defined in the present
invention are of interest for their antiangiogenic and/or vascular
permeability reducing effects. Such compounds of the invention are
expected to be useful in a wide range of disease states including
cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's
sarcoma, haemangioma, acute and chronic nephropathies, atheroma,
arterial restenosis, autoimmune diseases, acute inflammation,
excessive scar formation and adhesions, endometriosis,
dysfunctional uterine bleeding and ocular diseases with retinal
vessel proliferation. In particular such compounds of the invention
are expected to slow advantageously the growth of primary and
recurrent solid tumours of, for example, the colon, breast,
prostate, lungs and skin. More particularly such compounds of the
invention are expected to inhibit the growth of those primary and
recurrent solid tumours which are associated with VEGF especially
those tumours which are significantly dependent on VEGF for their
growth and spread, including for example, certain tumours of the
colon, breast, prostate, lung, vulva and skin.
[0113] In another aspect of the present invention compounds of
Formula I are expected to inhibit the growth of those primary and
recurrent solid tumours which are associated with EGF especially
those tumours which are significantly dependent on EGF for their
growth and spread.
[0114] In another aspect of the present invention compounds of
Formula I are expected to inhibit the growth of those primary and
recurrent solid tumours which are associated with both VEGF and EGF
especially those tumours which are significantly dependent on VEGF
and EGF for their growth and spread.
[0115] In addition to their use in therapeutic medicine, the
compounds of formula I and their pharmaceutically acceptable salts
are also useful as pharmacological tools in the development and
standardisation of in vitro and in vivo test systems for the
evaluation of the effects of inhibitors of VEGF receptor tyrosine
kinase activity in laboratory animals such as cats, dogs, rabbits,
monkeys, rats and mice, as part of the search for new therapeutic
agents.
[0116] It is to be understood that where the term "ether" is used
anywhere in this specification it refers to diethyl ether.
[0117] The invention will now be illustrated, but not limited, by
the following Examples in which, unless otherwise stated:--
[0118] (i) evaporations were carried out by rotary evaporation in
vacuo and work-up procedures were carried out after removal of
residual solids such as drying agents by filtration;
[0119] (ii) operations were carried out at ambient temperature,
that is in the range 18-25.degree. C. and under an atmosphere of an
inert gas such as argon;
[0120] (iii) column chromatography (by the flash procedure) and
medium pressure liquid chromatography (MPLC) were performed on
Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Arf.
9303) reversed-phase silica obtained from E. Merck, Darmstadt,
Germany;
[0121] (iv) yields are given for illustration only and are not
necessarily the maximum attainable;
[0122] (v) melting points are uncorrected and were determined using
a Mettler SP62 automatic melting point apparatus, an oil-bath
apparatus or a Koffler hot plate apparatus.
[0123] (vi) the structures of the end-products of the formula I
were confirmed by nuclear (generally proton) magnetic resonance
(NMR) and mass spectral techniques; proton magnetic resonance
chemical shift values were measured on the delta scale and peak
multiplicities are shown as follows: s, singlet; d, doublet, t,
triplet; m, multiplet; br, broad; q, quartet; NMR spectra were run
on a 400 MHz machine at 24.degree. C.
[0124] (vii) intermediates were not generally fully characterised
and purity was assessed by thin layer chromatography (TLC),
high-performance liquid chromatography (HPLC), infra-red (IR) or
NMR analysis;
[0125] (viii) the following abbreviations have been used:-- [0126]
DMF N,N-dimethylformamide [0127] DMSO dimethylsulphoxide [0128] THF
tetrahydrofuran [0129] TFA trifluoroacetic acid [0130] NMP
1-methyl-2-pyrrolidinone.]
EXAMPLE 1
[0131] TFA (3 ml) was added to a suspension of
4-(4-bromo-2-fluoroanilino)-7-(1-(tert-butoxycarbonyl)piperidin-4-ylmetho-
xy)-6-methoxyquinazoline (673 mg, 1.2 mmol) in methylene chloride
(10 ml). After stirring for 1 hour at ambient temperature, the
volatiles were removed under vacuum. The residue was triturated
with a mixture of water/ether. The organic layer was separated. The
aqueous layer washed again with ether. The aqueous layer was
adjusted to pH10 with 2N aqueous sodium hydroxide. The aqueous
layer was extracted with methylene chloride. The organic layer was
dried (MgSO.sub.4) and the solvent was removed under vacuum. The
solid was triturated with a mixture ether/petroleum ether (1/1),
filtered, washed with ether and dried under vacuum to give
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazolin-
e (390 mg, 70.5%).
[0132] MS-ESI: 461-463 [MH].sup.+
[0133] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.13-1.3 (m, 2H), 1.75
(d, 2H), 1.87-2.0 (m, 1H), 2.5 (d, 2H), 3.0 (d, 2H), 3.96 (s, 3H),
3.98 (d, 2H), 7.2 (s, 1H), 7.5 (dd, 1H), 7.55 (t, 1H), 7.68 (dd,
1H), 7.80 (s, 1H), 8.36 (s, 1H), 9.55 (br s, 1H) TABLE-US-00001
Elemental analysis: Found C 54.5 H 4.9 N 12.1
C.sub.21H.sub.22N.sub.4O.sub.2BrF Requires C 54.7 H 4.8 N 12.1%
[0134] The starting material was prepared as follows:
[0135] A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline
hydrochloride (8.35 g, 27.8 mmol), (prepared, for example, as
described in WO 97/22596, Example 1), and 4-bromo-2-fluoroaniline
(5.65 g, 29.7 mmol) in 2-propanol (200 ml) was heated at reflux for
4 hours. The resulting precipitate was collected by filtration,
washed with 2-propanol and then ether and dried under vacuum to
give 7-benzyloxy-4-(4-bromo-2-fluoroanilino)-6-methoxyquinazoline
hydrochloride (9.46 g, 78%).
[0136] .sup.1H NMR Spectrum: (DMSOd.sub.6; CD.sub.3COOD) 4.0 (s,
3H); 5.37 (s, 2H); 7.35-7.5 (m, 4H); 7.52-7.62 (m, 4H); 7.8 (d,
1H); 8.14 (9s, 1H); 8.79 (s, 1H)
[0137] MS-ESI: 456 [MH].sup.+ TABLE-US-00002 Elemental analysis:
Found C 54.0 H 3.7 N 8.7 C.sub.22H.sub.17N.sub.3O.sub.2BrF 0.9HCl
Requires C 54.2 H 3.7 N 8.6%
[0138] A solution of
7-benzyloxy-4-(4-bromo-2-fluoroanilino)-6-methoxyquinazoline
hydrochloride (9.4 g, 19.1 mmol) in TFA (90 ml) was heated at
reflux for 50 minutes. The mixture was allowed to cool and was
poured on to ice. The resulting precipitate was collected by
filtration and dissolved in methanol (70 ml). The solution was
adjusted to pH9-10 with concentrated aqueous ammonia solution. The
mixture was concentrated to half initial volume by evaporation. The
resulting precipitate was collected by filtration, washed with
water and then ether, and dried under vacuum to give
4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (5.66 g,
82%).
[0139] .sup.1H NMR Spectrum: (DMSOd.sub.6; CD.sub.3COOD) 3.95 (s,
3H); 7.09 (s, 1H); 7.48 (s, 1H); 7.54 (t, 1H); 7.64 (d, 1H); 7.79
(s, 1H); 8.31 (s, 1H)
[0140] MS-ESI: 366 [MH].sup.+ TABLE-US-00003 Elemental analysis:
Found C 49.5 H 3.1 N 11.3 C.sub.15H.sub.11N.sub.3O.sub.2BrF
Requires C 49.5 H 3.0 N 11.5%
[0141] While maintaining the temperature in the range 0-5.degree.
C., a solution of di-tert-butyl dicarbonate (41.7 g, 0.19 mol) in
ethyl acetate (75 ml) was added in portions to a solution of ethyl
4-piperidinecarboxylate (30 g, 0.19 mol) in ethyl acetate (150 ml)
cooled at 5.degree. C. After stirring for 48 hours at ambient
temperature, the mixture was poured onto water (300 ml). The
organic layer was separated, washed successively with water (200
ml), 0.1N aqueous hydrochloric acid (200 ml), saturated sodium
hydrogen carbonate (200 ml) and brine (200 ml), dried (MgSO.sub.4)
and evaporated to give ethyl
4-(1-(tert-butoxycarbonyl)piperidine)carboxylate (48 g, 98%).
[0142] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.25 (t, 3H); 1.45 (s,
9H) 1.55-1.70 (m, 2H); 1.8-2.0 (d, 2H); 2.35-2.5 (m, 1H); 2.7-2.95
(t, 2H); 3.9-4.1 (br s, 2H); 4.15 (q, 2H)
[0143] A solution of 1M lithium aluminium hydride in THF (133 ml,
0.133 mol) was added in portions to a solution of ethyl
4-(1-(tert-butoxycarbonyl)piperidine)carboxylate (48 g, 0.19 mol)
in dry THF (180 ml) cooled at 0.degree. C. After stirring at
0.degree. C. for 2 hours, water (30 ml) was added followed by 2N
sodium hydroxide (10 ml). The precipitate was removed by filtration
through diatomaceous earth and washed with ethyl acetate. The
filtrate washed with water, brine, dried (MgSO.sub.4) and
evaporated to give
1-(tert-butoxycarbonyl)-4-hydroxymethylpiperidine (36.3 g,
89%).
[0144] MS (EI): 215 [M.]+
[0145] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.05-1.2 (m, 2H);
1.35-1.55 (m, 10H); 1.6-1.8 (m, 2H); 2.6-2.8 (t, 2H) 3.4-3.6 (t,
2H); 4.0-4.2 (br s, 2H)
[0146] 1,4-Diazabicyclo[2.2.2]octane (42.4 g, 0.378 mol) was added
to a solution of 1-(tert-butoxycarbonyl)-4-hydroxymethylpiperidine
(52.5 g, 0.244 mol) in tert-butyl methyl ether (525 ml). After
stirring for 15 minutes at ambient temperature, the mixture was
cooled to 5.degree. C. and a solution of toluene sulphonyl chloride
(62.8 g, 0.33 mmol) in tert-butyl methyl ether (525 ml) was added
in portions over 2 hours while maintaining the temperature at
0.degree. C. After stirring for 1 hour at ambient temperature,
petroleum ether (1) was added. The precipitate was removed by
filtration. The filtrate was evaporated to give a solid. The solid
was dissolved in ether and washed successively with 0.5N aqueous
hydrochloric acid (2.times.500 ml), water, saturated sodium
hydrogen carbonate and brine, dried (MgSO.sub.4) and evaporated to
give
1-(tert-butoxycarbonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine
(76.7 g, 85%).
[0147] MS (ESI): 392 [MNa].sup.+
[0148] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.0-1.2 (m, 2H); 1.45 (s,
9H); 1.65 (d, 2H); 1.75-1.9 (m, 2H); 2.45 (s, 3H); 2.55-2.75 (m,
2H); 3.85 (d, 1H); 4.0-4.2 (br s, 2H); 7.35 (d, 2H); 7.8 (d,
2H)
[0149] Potassium carbonate (414 mg, 3 mmol) was added to a
suspension of
4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (546 mg,
1.5 mmol) in DMF (5 ml). After stirring for 10 minutes at ambient
temperature,
1-(tert-butoxycarbonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine
(636 mg, 1.72 mmol) was added and the mixture was heated at
95.degree. C. for 2 hours. After cooling, the mixture was poured
onto cooled water (20 ml). The precipitate was collected by
filtration, washed with water, and dried under vacuum to give
4-(4-bromo-2-fluoroanilino)-7-(1-(tert-butoxycarbonyl)piperidin-4-ylmetho-
xy)-6-methoxyquinazoline (665 mg, 79%).
[0150] MS-ESI: 561-563 [MH].sup.+
[0151] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.15-1.3 (m, 2H), 1.46
(s, 9H), 1.8 (d, 2H), 2.0-2.1 (m, 1H), 2.65-2.9 (m, 2H), 3.95 (s,
3H), 4.02 (br s, 2H), 4.05 (d, 2H), 7.2 (s, 1H), 7.48 (d, 1H), 7.55
(t, 1H), 7.65 (d, 1H), 7.8 (s, 1H), 8.35 (s, 1H), 9.55 (br s,
1H)
EXAMPLE 2a
[0152] A solution of 37% aqueous formaldehyde (50 .mu.l, 0.6 mmol)
followed by sodium cyanoborohydride (23 mg, 0.36 mmol) were added
to a solution of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin
ylmethoxy)quinazoline (139 mg, 0.3 mmol), (prepared as described in
Example 1), in a mixture of THF/methanol (1.4 ml/1.4 ml). After
stirring for 1 hour at ambient temperature, water was added and the
volatiles were removed under vacuum. The residue was triturated
with water, filtered, washed with water, and dried under vacuum.
The solid was purified by chromatography on neutral alumina eluting
with methylene chloride followed by methylene chloride/ethyl
acetate (1/1) followed by methylene chloride/ethyl acetate/methanol
(50/45/5). The fractions containing the expected product were
evaporated under vacuum. The resulting white solid was dissolved in
methylene chloride/methanol (3 ml/3 ml) and 3N hydrogen chloride in
ether (0.5 ml) was added. The volatiles were removed under vacuum.
The solid was triturated with ether, filtered, washed with ether
and dried under vacuum to give 4-(4-bromo-2-fluoroanilino)-6
-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride
(120 mg, 69%).
[0153] MS-ESI: 475-477 [MH].sup.+
[0154] The NMR spectrum of the protonated form of
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline hydrochloride shows the presence of 2 forms A and B in a
ratio A:B of approximately 9:1.
[0155] .sup.1H NMR Spectrum: (DMSOd.sub.6; CF.sub.3COOD) 1.55-1.7
(m, form A 2H); 1.85-2.0 (m, form B 4H); 2.03 (d, form A 2H);
2.08-2.14 (br s, form A 1H); 2.31-2.38 (br s, form B 1H); 2.79 (s,
form A 3H); 2.82 (s, form B 3H); 3.03 (t, form A 2H); 3.21 (br s,
form B 2H); 3.30 (br s, form B 2H); 3.52 (d, form A 2H); 4.02 (s,
3H); 4.12 (d, form A 2H); 4.30 (d, form B 2H); 7.41 (s, 1H);
7.5-7.65 (m, 2H); 7.81 (d, 1H); 8.20 (s, 1H); 8.88 (s, 1H)
TABLE-US-00004 Elemental analysis: Found C 46.0 H 5.2 N 9.6
C.sub.22H.sub.24N.sub.4O.sub.2BrF 0.3 H.sub.2O 2.65HCl Requires C
45.8 H 4.8 N 9.7%
EXAMPLE 2b
[0156] 37% Aqueous formaldehyde (3.5 ml, 42 mmol) was added to a
solution of
4-(4-bromo-2-fluoroanilino)-7-(1-(tert-butoxycarbonyl)piperidin-4-ylme-
thoxy)-6-methoxyquinazoline (3.49 g, 6.22 mmol), (prepared as
described for the starting material in Example 1), in formic acid
(35 ml). After heating at 95.degree. C. for 4 hours the volatiles
were removed under vacuum. The residue was suspended in water and
the mixture was adjusted to pH10.5 by slow addition of a solution
of 2N sodium hydroxide. The suspension was extracted with ethyl
acetate. The organic layer washed with brine, dried MgSO.sub.4 and
evaporated to give
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline (2.61 g, 88%).
[0157] MS-ESI: 475-477 [MH].sup.+
[0158] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H), 1.8
(d, 2H), 1.7-1.9 (m, 1H), 1.95 (t, 2H), 2.2 (s, 3H), 2.85 (d, 2H),
3.96 (s, 3H), 4.05 (d, 2H), 7.19 (s, 1H), 7.5 (d, 1H), 7.55 (t,
1H), 7.67 (d, 1H), 7.81 (s, 1H), 8.37 (s, 1H), 9.54 (s, 1H)
TABLE-US-00005 Elemental analysis: Found C 55.4 H 5.1 N 11.6
C.sub.22H.sub.24N.sub.4O.sub.2BrF Requires C 55.6 H 5.1 N 11.8%
EXAMPLE 2c
[0159] A suspension of
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
(200 mg, 0.62 mmol) and 4-bromo-2-fluoroaniline (142 mg; 0.74 mmol
in isopropanol (3 ml) containing 6N hydrogen chloride in
isopropanol (110 .mu.l, 0.68 ml) was heated at reflux for 1.5
hours. After cooling, the precipitate was collected by filtration,
washed with isopropanol followed by ether and dried under vacuum to
give
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline hydrochloride (304 mg, 90%). TABLE-US-00006 Elemental
analysis: Found C 47.9 H 4.9 N 10.0
C.sub.22H.sub.24N.sub.4O.sub.2BrF 0.5H.sub.2O 1.8HCl Requires C
48.2 H 5.0 N 10.1%
0.08 isopropanol
[0160] The NMR spectrum of the protonated form of
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline hydrochloride shows the presence of two forms A and B in
a ratio A:B of approximately 9:1.
[0161] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.6-1.78 (m, form A 2H);
1.81-1.93 (br s, form B 4H); 1.94-2.07 (d, form A 2H); 2.08-2.23
(br s, form A 1H); 2.29-2.37 (br s, form B 1H); 2.73 (d, form A
3H); 2.77 (d, form B 3H); 2.93-3.10 (q, form A 2H); 3.21 (br s,
form B 2H); 3.27 (br s, form B 2H); 3.42-3.48 (d, form A 2H); 4.04
(s, 3H); 4.10 (d, form A 2H), 4.29 (d, form B 2H); 7.49 (s, 1H);
7.53-7.61 (m, 2H); 7.78 (d, 1H); 8.47 (s, 1H); 8.81 (s, 1H); 10.48
(br s, form A 1H); 10.79 (br s, form B 1H); 11.90 (br s, 1H)
[0162] For another NMR reading, some solid potassium carbonate was
added into the DMSO solution of the
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline hydrochloride described above, in order to release the
free base in the NMR tube. The NMR spectrum was then recorded again
and showed only one form as described below:
[0163] .sup.1H NMR Spectrum: (DMSOd.sub.6; solid potassium
carbonate) 1.3-1.45 (m, 2H); 1.75 (d, 2H); 1.7-1.9 (m, 1H); 1.89
(t, 2H); 2.18 (s, 3H); 2.8 (d, 2H); 3.98 (s, 3H); 4.0 (d, 2H); 7.2
(s, 1H); 7.48 (d, 1H); 7.55 (t, 1H); 7.68 (d, 1H); 7.8 (s, 1H);
8.35 (s, 1H); 9.75 (s, 1H)
[0164] A sample of
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline (free base) was generated from the
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline hydrochloride, (prepared as described above), as
follows:
[0165]
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmet-
hoxyquinazoline hydrochloride (50 mg) was suspended in methylene
chloride (2 ml) and washed with saturated sodium hydrogen
carbonate. The methylene chloride solution was dried (MgSO.sub.4)
and the volatiles were removed by evaporation to give
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline (free base). The NMR of the free base so generated shows
only one form as described below:
[0166] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H); 1.76
(d, 2H); 1.7-1.9 (m, 1H); 1.9 (t, 2H); 2.19 (s, 3H); 2.8 (d, 2H);
3.95 (s, 3H); 4.02 (d, 2H); 7.2 (s, 1H); 7.48 (d, 1H); 7.55 (t,
1H); 7.68 (dd, 1H); 7.8 (s, 1H); 8.38 (s, 1H); 9.55 (br s, 1H)
[0167] For another NMR reading, some CF.sub.3COOD was added into
the NMR DMSO solution of the
4-(4-bromo-2-fluoroanilino-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qui-
nazoline (free base) described above and the NMR spectrum was
recorded again. The spectrum of the protonated form of the
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline trifluoroacetate salt so obtained shows the presence of
two forms A and B in a ratio A:B of approximately 9:1.
[0168] .sup.1H NMR Spectrum: (DMSOd.sub.6; CF.sub.3COOD) 1.5-1.7
(m, form A 2H); 1.93 (br s, form B 4H); 2.0-2.1 (d, form A 2H);
2.17 (br s, form A 1H); 2.35 (br s, form B 1H); 2.71 (s, form A
3H); 2.73 (s, form B 3H); 2.97-3.09 (t, form A 2H); 3.23 (br s,
form B 2H); 3.34 (br s, form B 2H); 3.47-3.57 (d, form A 2H); 4.02
(s, 3H); 4.15 (d, form A 2H); 4.30 (d, form B 2H); 7.2 (s, 1H);
7.3-7.5 (m, 2H); 7.6 (d, 1H); 7.9 (s, 1H); 8.7 (s, 1H)
[0169] The starting material was prepared as follows:
[0170]
1-tert-Butoxycarbonyl)-4-(4-methylphenylsulphonyloxymethyl)piperid-
ine (40 g, 0.11 mol), (prepared as described for the starting
material in Example 1), was added to a suspension of ethyl
4-hydroxy-3-methoxybenzoate (19.6 g, 0.1 mol) and potassium
carbonate (28 g, 0.2 mol) in dry DMF (200 ml). After stirring at
95.degree. C. for 2.5 hours, the mixture was cooled to ambient
temperature and partitioned between water and ethyl acetate/ether.
The organic layer washed with water, brine, dried (MgSO.sub.4) and
evaporated. The resulting oil was crystallised from petroleum ether
and the suspension was stored overnight at 5.degree. C. The solid
was collected by filtration, washed with petroleum ether and dried
under vacuum to give ethyl
4-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-3-methoxybenzoate
(35 g, 89%).
[0171] m.p. 81-83.degree. C.
[0172] MS (ESI): 416 [MNa].sup.+
[0173] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.2-1.35 (m, 2H); 1.4 (t,
3H); 1.48 (s, 9H); 1.8-1.9 (d, 2H); 2.0-2.15 (m, 2H); 2.75 (t, 2H);
3.9 (d, 2H); 3.95 (s, 3H); 4.05-4.25 (br s, 2H); 4.35 (q, 2H); 6.85
(d, 1H); 7.55 (s, 1H); 7.65 (d, 1H) TABLE-US-00007 Elemental
analysis: Found C 63.4 H 8.0 N 3.5 C.sub.21H.sub.31NO.sub.6
0.3H.sub.2O Requires C 63.2 H 8.0 N 3.5%
[0174] Formaldehyde (12M, 37% in water, 35 ml, 420 mmol) was added
to a solution of ethyl
4-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-3-methoxybenzoate
(35 g, 89 mmol) in formic acid (35 ml). After stirring at
95.degree. C. for 3 hours, the volatiles were removed by
evaporation. The residue was dissolved in methylene chloride and 3M
hydrogen chloride in ether (40 ml, 120 mmol) was added. After
dilution with ether, the mixture was triturated until a solid was
formed. The solid was collected by filtration, washed with ether
and dried under vacuum overnight at 50.degree. C. to give ethyl
3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate (30.6 g,
quant.).
[0175] MS (ESI): 308 [MH].sup.+
[0176] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.29 (t, 3H); 1.5-1.7
(m, 2H); 1.95 (d, 2H); 2.0-2.15 (br s, 1H); 2.72 (s, 3H); 2.9-3.1
(m, 2H); 3.35-3.5 (br s, 2H); 3.85 (s, 3H); 3.9-4.05 (br s, 2H);
4.3 (q, 2H); 7.1 (d, 1H); 7.48 (s, 1H); 7.6 (d, 1H)
[0177] A solution of ethyl
3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate (30.6 g, 89
mmol) in methylene chloride (75 ml) was cooled to 0-5.degree. C.
TFA (37.5 ml) was added followed by the dropwise addition over 15
minutes of a solution of fuming 24N nitric acid (7.42 ml, 178 mmol)
in methylene chloride (15 ml). After completion of the addition,
the solution was allowed to warm up and stirred at ambient
temperature for 2 hours. The volatiles were removed under vacuum
and the residue was dissolved in methylene chloride (50 ml). The
solution was cooled to 0-5.degree. C. and ether was added. The
precipitate was collected by filtration, and dried under vacuum at
50.degree. C. The solid was dissolved in methylene chloride (500
ml) and 3M hydrogen chloride in ether (30 ml) was added followed by
ether (500 ml). The solid was collected by filtration and dried
under vacuum at 50.degree. C. to give ethyl
3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-6-nitrobenzoate (28.4
g, 82%).
[0178] MS (ESI): 353 [MH].sup.+
[0179] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3 (t, 3H); 1.45-1.65
(m, 2H); 1.75-2.1 (m, 3H); 2.75 (s, 3H); 2.9-3.05 (m, 2H); 3.4-3.5
(d, 2H); 3.95 (s, 3H); 4.05 (d, 2H); 4.3 (q, 2H); 7.32 (s, 1H);
7.66 (s, 1H)
[0180] A suspension of ethyl
3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-6-nitrobenzoate (3.89
g, 10 mmol) in methanol (80 ml) containing 10% platinum on
activated carbon (50% wet) (389 mg) was hydrogenated at 1.8
atmospheres pressure until uptake of hydrogen ceased. The mixture
was filtered and the filtrate was evaporated. The residue was
dissolved in water (30 ml) and adjusted to pH10 with a saturated
solution of sodium hydrogen carbonate. The mixture was diluted with
ethyl acetate/ether (1/1) and the organic layer was separated. The
aqueous layer was further extracted with ethyl acetate/ether and
the organic layers were combined. The organic layers were washed
with water, brine, dried (MgSO.sub.4), filtered and evaporated. The
resulting solid was triturated in a mixture of ether/petroleum
ether, filtered, washed with petroleum ether and dried under vacuum
at 60.degree. C. to give ethyl
6-amino-3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate (2.58
g, 80%).
[0181] m.p. 111-112.degree. C.
[0182] MS (ESI): 323 [MH].sup.+
[0183] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.35 (t, 3H); 1.4-1.5 (m,
2H); 1.85 (m, 3H); 1.95 (t, 2H); 2.29 (s, 3H); 2.9 (d, 2H); 3.8 (s,
3H); 3.85 (d, 2H); 4.3 (q, 2H); 5.55 (br s, 2H); 6.13 (s, 1H); 7.33
(s, 1H) TABLE-US-00008 Elemental analysis: Found C 62.8 H 8.5 N 8.3
C.sub.17H.sub.26N.sub.2O.sub.4 0.2H.sub.2O Requires C 62.6 H 8.2 N
8.6%
[0184] A solution of ethyl
6-amino-3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate (16.1
g, 50 mmol) in 2-methoxyethanol (160 ml) containing formamidine
acetate (5.2 g, 50 mmol) was heated at 115.degree. C. for 2 hours.
Formamidine acetate (10.4 g, 100 mmol) was added in portions every
30 minutes over 4 hours. Heating was prolonged for 30 minutes after
the last addition. After cooling, the volatiles were removed under
vacuum. The solid was dissolved in ethanol (100 ml) and methylene
chloride (50 ml). The precipitate was removed by filtration and the
filtrate was concentrated to a final volume of 100 ml. The
suspension was cooled to 5.degree. C. and the solid was collected
by filtration, washed with cold ethanol followed by ether and dried
under vacuum overnight at 60.degree. C. to give
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4-one
(12.7 g, 70%).
[0185] MS (ESI): 304 [MH].sup.+
[0186] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.25-1.4 (m, 2H); 1.75
(d, 2H); 1.9 (t, 1H); 1.9 (s, 3H); 2.16 (s, 2H); 2.8 (d, 2H); 3.9
(s, 3H); 4.0 (d, 2H); 7.11 (s, 1H); 7.44 (s, 1H); 7.97 (s, 1H)
[0187] A solution of
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4-one
(2.8 g, 9.24 mmol) in thionyl chloride (28 ml) containing DMF (280
.mu.l) was heated at reflux at 85.degree. C. for 1 hour. After
cooling, the volatiles were removed by evaporation. The precipitate
was triturated with ether, filtered, washed with ether and dried
under vacuum. The solid was dissolved in methylene chloride and
saturated aqueous sodium hydrogen carbonate was added. The organic
layer was separated, washed with water, brine, dried (MgSO.sub.4)
and evaporated to give
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
(2.9 g, 98%).
[0188] MS (ESI): 322 [MH].sup.+
[0189] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.5 (m, 2H);
1.75-1.9 (m, 3H); 2.0 (t, 1H); 2.25 (s, 3H); 2.85 (d, 2H); 4.02 (s,
3H); 4.12 (d, 2H); 7.41 (s, 1H); 7.46 (s, 1H); 8.9 (s, 1H)
[0190] Alternatively, the
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4
-one can be prepared as follows:
[0191] Sodium hydride (1.44 g of a 60% suspension in mineral oil,
36 mmol) was added in portions over 20 minutes to a solution of
7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.46 g, 30
mmol), (prepared, for example, as described in WO 97/22596, Example
1), in DMF (70 ml) and the mixture was stirred for 1.5 hours.
Chloromethyl pivalate (5.65 g, 37.5 mmol) was added in portions and
the mixture stirred for 2 hours at ambient temperature. The mixture
was diluted with ethyl acetate (100 ml) and poured onto ice/water
(400 ml) and 2N hydrochloric acid (4 ml). The organic layer was
separated and the aqueous layer extracted with ethyl acetate, the
combined extracts were washed with brine, dried (MgSO.sub.4) and
the solvent removed by evaporation. The residue was triturated with
a mixture of ether and petroleum ether, the solid was collected by
filtration and dried under vacuum to give
7-benzyloxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one
(10 g, 84%).
[0192] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.11 (s, 9H); 3.89 (s,
3H); 5.3 (s, 2H); 5.9 (s, 2H); 7.27 (s, 1H); 7.35 (m, 1H); 7.47 (t,
2H); 7.49 (d, 2H); 7.51 (s, 1H); 8.34 (s, 1H)
[0193] A mixture of
7-benzyloxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one
(7 g, 17.7 mmol) and 10% palladium-on-charcoal catalyst (700 mg) in
ethyl acetate (250 ml), DMF (50 ml), methanol (50 ml)) and acetic
acid (0.7 ml) was stirred under hydrogen at atmospheric pressure
for 40 minutes. The catalyst was removed by filtration and the
solvent removed from the filtrate by evaporation. The residue was
triturated with ether, collected by filtration and dried under
vacuum to give
7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one
(4.36 g, 80%).
[0194] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.1 (s, 9H); 3.89 (s,
3H); 5.89 (s, 2H); 7.0 (s, 1H); 7.48 (s, 1H); 8.5 (s, 1H)
[0195] Triphenylphosphine (1.7 g, 6.5 mmol) was added under
nitrogen to a suspension of
7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one
(1.53 g, 5 mmol) in methylene chloride (20 ml), followed by the
addition of 1-(tert-butoxycarbonyl)-4-(hydroxymethyl)piperidine
(1.29 g, 6 mmol), (prepared as described for the starting material
in Example 1), and by a solution of diethyl azodicarboxylate (1.13
g, 6.5 mmol) in methylene chloride (5 ml). After stirring for 30
minutes at ambient temperature, the reaction mixture was poured
onto a column of silica and was eluted with ethyl acetate/petroleum
ether (1/1 followed by 6/5, 6/4 and 7/3). Evaporation of the
fractions containing the expected product led to an oil that
crystallised following trituration with pentane. The solid was
collected by filtration and dried under vacuum to give
7-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)
6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (232
g, 92%).
[0196] MS-ESI: 526 [MNa].sup.+
[0197] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.20 (s, 9H), 1.2-1.35
(m, 2H), 1.43 (s, 9H), 1.87 (d, 2H), 2.05-2.2 (m, 1H), 2.75 (t,
2H), 3.96 (d, 2H), 3.97 (s, 3H), 4.1-4.25 (br s, 2H), 5.95 (s, 2H),
7.07 (s, 1H), 7.63 (s, 1H), 8.17 (s, 1H) TABLE-US-00009 Elemental
analysis: Found C 61.8 H 7.5 N 8.3 C.sub.26H.sub.37N.sub.3O.sub.7
Requires C 62.0 H 7.4 N 8.3%
[0198] A solution of
7-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-6-methoxy-3-((pivaloylox-
y)methyl)-3,4-dihydroquinazolin-4-one (2.32 g, 4.6 mmol) in
methylene chloride (23 ml) containing TFA (5 ml) was stirred at
ambient temperature for 1 hour. The volatiles were removed under
vacuum. The residue was partitioned between ethyl acetate and
sodium hydrogen carbonate. The organic solvent was removed under
vacuum and the residue was filtered. The precipitate washed with
water, and dried under vacuum. The solid was azeotroped with
toluene and dried under vacuum to give
6-methoxy-7-(piperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroqu-
inazolin-4-one (1.7 g, 92%).
[0199] MS-ESI: 404 [MH].sup.+
[0200] .sup.1H NMR Spectrum: (DMSOd.sub.6; CF.sub.3COOD) 1.15 (s,
9H), 1.45-1.6 (m, 2H), 1.95 (d, 2H), 2.1-2.25 (m, 1H), 2.95 (t,
2H), 3.35 (d, 2H), 3.95 (s, 3H), 4.1 (d, 2H), 5.95 (s, 2H), 7.23
(s, 1H), 7.54 (s, 1H), 8.45 (s, 1H)
[0201] A 37% aqueous solution of formaldehyde (501 .mu.l, 6 mmol)
followed by sodium cyanoborohydride (228 mg, 3.6 mmol) were added
in portions to a solution of
6-methoxy-7-(piperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroqu-
inazolin-4-one (1.21 g; 3 mmol) in a mixture of THF/methanol (10
ml/10 ml). After stirring for 30 minutes at ambient temperature,
the organic solvents were removed under vacuum and the residue was
partitioned between methylene chloride and water. The organic layer
was separated, washed with water and brine, dried (MgSO.sub.4) and
the volatiles were removed by evaporation. The residue was
triturated with ether and the resulting solid was collected by
filtration, washed with ether and dried under vacuum to give
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-d-
ihydroquinazolin-4-one (1.02 g, 82%).
[0202] MS-ESI: 418 [MH].sup.+
[0203] .sup.1H NMR Spectrum: (CDCl.sub.3) 1.19 (s, 9H), 1.4-1.55
(m, 2H), 1.9 (d, 2H), 2.0 (t, 2H), 1.85-2.1 (m, 1H), 2.3 (s, 3H),
2.92 (d, 2H), 3.96 (s, 3H), 3.99 (d, 2H), 5.94 (s, 2H), 7.08 (s,
1H), 7.63 (s, 1H), 8.17 (s, 1H)
[0204] A saturated solution of ammonia in methanol (14 ml) was
added to a solution of 6
methoxy-7-(1-methylpiperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-(di-
hydroquinazolin-4-one (1.38 g, 3.3 mmol) in methanol (5 ml). After
stirring for 20 hours at ambient temperature, the suspension was
diluted with methylene chloride (10 ml). The solution was filtered.
The filtrate was evaporated under vacuum and the residue was
triturated with ether, collected by filtration washed with ether
and dried under vacuum to give
6-methoxy-7-(1-methylpiperidin-ylmethoxy)-3,4-dihydroquinazolin-4-one
(910 mg, 83%).
[0205] MS-ESI: 304 [MH].sup.+
[0206] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H), 1.75
(d, 2H), 1.7-1.85 (m, 1H), 1.9 (t, 2H), 2.2 (s, 3H), 2.8 (d, 2H),
3.9 (s, 3H), 4.0 (d, 2H), 7.13 (s, 1H), 7.45 (s, 1H), 7.99 (s,
1H)
EXAMPLE 3a
[0207] 3.5M Hydrogen chloride in ethanol (75 .mu.l, 0.26 mmol) was
added to a suspension of
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (80
mg, 0.25 mmol), (prepared as described for the starting material in
Example 2c), in isopropanol (3 ml), the mixture was heated to
50.degree. C. and 4-chloro-2-fluoroaniline (44 mg, 0.3 mmol) was
added. The mixture was heated at reflux for 30 minutes. After
cooling, the mixture was diluted with ether (3 ml). The precipitate
was collected by filtration, washed with ether and dried under
vacuum to give
4-(4-chloro-2-fluoroanifino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline hydrochloride (105 mg, 82%).
[0208] MS-ESI: 431-433 [MH].sup.+
[0209] The NMR spectrum of the protonated form of
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline hydrochloride shows the presence of two forms A and B in
a ratio A:B of approximately 9:1.
[0210] .sup.1H NMR Spectrum: (DMSOd.sub.6; CF.sub.3COOD) 1.55-1.7
(m, form A 2H), 1.85-2.0 (m, form B 4H), 2.05 (d, form A 2H),
2.1-2.2 (m, form A 1H), 2.35 (s, 3H); 2.79 (s, form A 3H), 2.82 (s,
form B 3H), 3.03 (t, form A 2H), 3.2-3.3 (m, form B 2H); 3.3-3.4
(m, form B 2H), 3.52 (d, form A 2H), 4.02 (s, 3H), 4.13 (d, form A
2H), 4.3 (d, form B 2H), 7.41 (s, 1H), 7.47 (dd, 1H), 7.63 (t, 1H),
7.69 (dd, 1H), 8.19 (s, 1H), 8.88 (s, 1H) TABLE-US-00010 Elemental
analysis: Found C 51.8 H 5.6 N 10.9
C.sub.22H.sub.24N.sub.4O.sub.2C1F 0.4H.sub.2O 2HCl Requires C 51.7
H 5.3 N 11.0%
EXAMPLE 3b
[0211] An alternative method of preparation is as follows:
[0212] Triphenylphosphine (615 mg, 2.3 mmol) followed by diethyl
azodicarboxylate (369 .mu.l, 2.3 mmol) were added to a solution of
4-hydroxymethyl-1-methylpiperidine (151 mg, 1.1 mmol), (J Med. Chem
1973, 16, 156), and
4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250
mg, 0.78 mmol), (prepared as described for the starting material in
Example 7), in methylene chloride (5 ml). After stirring for 30
minutes at ambient temperature, 4-hydroxymethyl-1-methylpiperidine
(51 mg, 0.39 mmol), triphenylphosphine (102 mg, 0.39 mmol) and
diethyl azodicarboxylate (61 .mu.l, 0.39 mmol) were added. After
stirring for 15 minutes, the volatiles were removed under vacuum
and the residue was purified by column chromatography eluting with
methylene chloride/acetonitrile/methanol (70/10/20 followed by
75/5/20 and 80/0/20). The fractions containing the expected product
were combined and the volatiles were removed by evaporation. The
residue was dissolved in a mixture of methylene chloride and
methanol and 5M hydrogen chloride in isopropanol was added. The
suspension was concentrated and the solid was collected by
filtration, washed with ether and dried under vacuum to give
4-(4-chloro-2-fluoroanilino,-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline hydrochloride (16 mg, 4%).
EXAMPLE 4
[0213] Under argon, sodium hydride (60%, 372 mg, 9.3 mmol) was
added to a solution of 4 bromo-2,6-difluoroaniline (1.67 g, 8.08
mmol) in DMF. After stirring for 30 minutes at ambient temperature,
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
(1.3 g, 4.04 mmol) was added and stirring was continued for a
further 20 hours. The mixture was poured onto water (130 ml) and
extracted with ethyl acetate. The organic layers were washed with
water, brine, dried (MgSO.sub.4) and the volatiles were removed by
evaporation. The residue was purified by column chromatography on
silica, eluting with methylene chloride/methanol (95/5) followed by
methylene chloride/methanol containing ammonia (1%) (90/10). The
fractions containing the expected product were combined and
evaporated. The residue was triturated with ether, collected by
filtration, washed with ether and dried under vacuum at 50.degree.
C. to give
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethox-
y)quinazoline (1.4 g, 70%).
[0214] MS-ESI: 493-495 [MH].sup.+
[0215] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H), 1.8
(d, 2H), 1.7-1.9 (m, 1H), 1.9 (t, 2H), 2.17 (s, 3H), 2.8 (d, 2H),
3.95 (s, 3H), 4.02 (d, 2H), 7.2 (s, 1H), 7.63 (s, 1H), 7.6 (s, 1H),
7.82 (s, 1H), 8.35 (s, 1H) TABLE-US-00011 Elemental analysis: Found
C 53.8 H 4.8 N 11.3 C.sub.22H.sub.23N.sub.4O.sub.2BrF.sub.2
Requires C 53.6 H 4.7 N 11.4%
EXAMPLE 5
[0216] Using an analogous procedure to that described in Example 4,
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
(246 mg, 0.764 mmol), (prepared as described for the starting
material in Example 2c), was reacted with
4-chloro-2,6-difluoroaniline (250 mg, 1.53 mmol), (see WO 97/30035
Example 15), in DMF (9 ml) and in the presence of sodium hydride
(60%, 76.5 mg, 1.9 mmol) to give
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmetho-
xy)quinazoline (210 mg, 61%).
[0217] MS-ESI: 449-451 [MH].sup.+
[0218] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H), 1.8
(d, 2H) 1.7-1.9 (m, 1H), 1.9 (t, 2H), 2.2 (s, 3H); 2.8 (d, 2H),
3.96 (s, 3H), 4.02 (d, 2H), 7.21 (s, 1H), 7.52 (s, 1H), 7.54 (s,
1H), 7.82 (s, 1H), 8.35 (s, 1H) TABLE-US-00012 Elemental analysis:
Found C 59.0 H 5.3 N 12.5 C.sub.22H.sub.23N.sub.4O.sub.2ClF.sub.2
Requires C 58.9 H 5.2 N 12.5%
[0219] The starting material was prepared as follows:
[0220] 4-Chloro-2,6-difluoroaniline hydrochloride (see WO 97/30035
Example 15) was partitioned between methylene chloride and water
and aqueous sodium hydrogen carbonate was added until the pH of the
aqueous layer was approximately 9. The organic layer was separated,
washed with brine, dried (MgSO.sub.4) and evaporated to give
4-chloro-2,6-difluoroaniline free base.
EXAMPLE 6
[0221] A suspension of
4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
(200 mg, 0.622 mmol), (prepared as described for the starting
material in Example 2c) and 2-fluoro-4-methylaniline (94 mg, 0.764
mmol) in isopropanol (5 ml) containing 6.2M hydrogen chloride in
isopropanol (110 .mu.l) was stirred at 80.degree. C. for 1.5 hours.
After cooling, the precipitate was collected by filtration, washed
with isopropanol, followed by ether and dried under vacuum. The
solid was purified by column chromatography, eluting with methylene
chloride/methanol (90/10) followed by 5% ammonia in
methanol/methylene chloride (10/90). Evaporation of the fractions
containing the expected product gave
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)q-
uinazoline (170 mg, 61%).
[0222] MS-ESI: 411 [MH].sup.+
[0223] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.3-1.45 (m, 2H), 1.8
(d, 2H), 1.7-1.9 (m, 1H), 1.9 (t, 2H), 2.2 (s, 3H), 2.35 (s, 3H),
2.8 (d, 2H), 3.95 (s, 3H), 4.01 (d, 2H), 7.1 (d, 1H), 7.13 (d, 1H),
7.16 (s, 1H), 7.4 (t, 1H), 7.81 (s, 1H), 8.32 (s, 1H), 9.4 (s, 1H)
TABLE-US-00013 Elemental analysis: Found C 66.5 H 6.7 N 13.7
C.sub.23H.sub.27N.sub.4O.sub.2F 0.3H.sub.2O Requires C 66.4 H 6.7 N
13.5%
EXAMPLE 7
[0224] 1-tert-Butoxycarbonyl-4-hydroxymethylpiperidine (590 mg,
2.75 mmol), (prepared as described for the starting material in
Example 1), followed by triphenylphosphine (1.2 g, 4.58 mmol) and
diethyl azodicarboxylate (0.72 ml, 4.58 mmol) were added to a
solution of
4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (585
mg, 1.83 mmol) in methylene chloride (20 ml). After stirring for 1
hour at ambient temperature, further triphenylphosphine (239 mg,
0.91 mmol) and diethyl azodicarboxylate (0.14 ml, 0.91 mmol) were
added. After stirring for 1.5 hours, the volatiles were removed
under vacuum and the residue was purified by column chromatography
eluting with ethyl acetate/methylene chloride (1/1). The crude
product was used directly in the next step.
[0225] A solution of the crude product in methylene chloride (15
ml) containing TFA (4.5 ml) was stirred at ambient temperature for
1.5 hours. The volatiles were removed under vacuum. The residue was
partitioned between water and ethyl acetate. The aqueous layer was
adjusted to pH9.5 with 2N sodium hydroxide. The organic layer was
separated, washed with water, followed by brine, dried (MgSO.sub.4)
and evaporated to give
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoli-
ne.
[0226] MS-ESI: 417-419 [MH].sup.+
[0227] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.1-1.3 (m, 2H), 1.75
(d, 2H), 1.85-2.0 (br s, 1H), 2.55 (d, 2H), 2.95 (d, 2H), 3.95 (s,
3H), 4.0 (d, 2H), 7.2 (s, 1H), 7.35 (dd, 1H), 7.55 (dd, 1H), 7.6
(t, 1H), 7.8 (s, 1H), 8.35 (s, 1H), 9.55 (s, 1H)
[0228] The hydrochloride salt was made as follows:
[0229]
4-(4-Chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)qu-
inazoline was dissolved in a mixture of methanol/methylene chloride
and 6M hydrogen chloride in ether was added. The volatiles were
removed under vacuum, the residue was triturated with ether,
collected by filtration, washed with ether and dried under vacuum
to give
4-(4-chloro-2-fluoro)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline
hydrochloride (390 mg, 47% over 2 steps). TABLE-US-00014 Elemental
analysis: Found C 50.4 H 5.2 N 11.0
C.sub.21H.sub.22O.sub.2N.sub.4ClF 2.25HCl Requires C 50.6 H 4.9 N
11.2%
[0230] The starting material was prepared as follows:
[0231] A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline
hydrochloride (1.2 g, 4 mmol), (prepared as described in WO
97/22596, Example 1), and 4-chloro-2-fluoroaniline (444 .mu.l, 4
mmol) in 2-propanol (40 ml) was heated at reflux for 1.5 hours.
After cooling, the precipitate was collected by filtration, washed
with 2-propanol then ether and dried under vacuum to give
7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline
hydrochloride (1.13 g, 64%).
[0232] m.p. 239-242.degree. C.
[0233] .sup.1H NMR Spectrum: (DMSOd.sub.6) 4.0 (s, 3H); 5.36 (s,
2H); 7.39-7.52 (m, 9H); 8.1 (s, 1H); 8.75 (s, 1H)
[0234] MS ESI: 410 [MH].sup.+ TABLE-US-00015 Elemental analysis:
Found C 59.2 H 4.3 N 94 C.sub.22H.sub.17N.sub.3O.sub.2ClF 1HCl
Requires C 59.2 H 4.1 N 9.4%
[0235] A solution of
7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline
hydrochloride (892 mg, 2 mmol) in TFA (10 ml) was heated at reflux
for 50 minutes. After cooling, the mixture was poured onto ice. The
precipitate was collected by filtration, dissolved in methanol (10
ml) and basified to pH11 with aqueous ammonia. After concentration
by evaporation, the solid product was collected by filtration,
washed with water then ether and dried under vacuum to give
4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline as a
yellow solid (460 mg, 72%).
[0236] m.p. 141-143.degree. C.
[0237] MS-ESI: 320-322 [MH].sup.+
[0238] .sup.1H NMR Spectrum: (DMSOd.sub.6) 3.95 (s, 3H); 7.05 (s,
1H); 7.35 (d, 1H); 7.54-7.59 (m, 2H); 7.78 (s, 1H); 8.29 (s,
1H)
EXAMPLE 8
[0239] A suspension of
7-(1-(tert-butoxycarbonyl)piperidin-4ylmethoxy)-4-(2-fluoro-4-methylanili-
no)-6-methoxyquinazoline (318 mg, 0.64 mmol) in methylene chloride
(5 ml) containing TFA (2.5 ml) was stirred at ambient temperature
for 2 hours. The volatiles were removed under vacuum and the
residue was partitioned between methylene chloride and water. The
aqueous layer was adjusted to pH10-11. The organic layer was
separated, washed with water, brine, dried (MgSO.sub.4) and the
volatiles were removed by evaporation to give
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoli-
ne (220 mg, 87%).
[0240] MS-ESI: 397 [MH]+
[0241] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.15-1.3 (m, 2H); 1.75
(d, 2H); 1.85-2.0 (m, 1H); 2.4 (s, 3H); 3.0 (d, 2H); 3.3-3.4 (d,
2H); 3.95 (s, 3H); 4.0 (d, 2H); 7.04 (d, 1H); 7.15 (d, 1H); 7.17
(s, 1H); 7.4 (t, 1H); 7.8 (s, 1H); 8.3 (s, 1H); 9.4 (s, 1H)
[0242] The starting material was prepared as follows:
[0243] Using an analogous procedure to that described in Example 6,
7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (1.55 g,
5.15 mmol), (prepared, for example, as described in WO 97/22596,
Example 1), was reacted with 2-fluoro-4-methylaniline (700 mg, 5.67
mmol) in isopropanol (90 ml) containing 6.2M hydrogen chloride in
isopropanol (80 .mu.l, 0.51 mmol) to give
7-benzyloxy-4-(2-fluoro-4-methylanilino)-6-methoxyquinazoline
hydrochloride (2 g, 91%).
[0244] MS-ESI: 390 [MH].sup.+
[0245] .sup.1H NMR Spectrum: (DMSOd.sub.6) 2.4 (s, 3H), 4.01 (s,
3H), 7.15 (d, 1H), 7.25 (d, 1H), 7.35-7.6 (m, 7H), 8.3 (s, 1H),
8.78 (s, 1H)
[0246] A solution of
7-benzyloxy-4-(2-fluoro-4-methylanilino)-6-methoxyquinazoline
hydrochloride (2 g, 4.7 mmol) in TFA (20 ml) was heated at
80.degree. C. for 5 hours and stirred at ambient temperature
overnight. The volatiles were removed under vacuum and the residue
was suspended in water (50 ml). Solid sodium hydrogen carbonate was
added until the pH was approximately 7. The precipitate was then
collected by filtration, washed with water and dried under vacuum.
The solid was purified by column chromatography eluting with
methanol/methylene chloride (5/95). After removal of the solvent by
evaporation, the solid was triturated with ether, collected by
filtration, washed with ether and dried under vacuum to give
4-(2-fluoro-4-methylanilino)-7-hydroxy-methoxyquinazoline (1.04 g,
74%).
[0247] MS-ESI: 300 [MH].sup.+
[0248] .sup.1H NM Spectrum: (DMSOd.sub.6) 2.4 (s, 3H), 4.0 (s, 3H),
7.15 (d, 1H), 7.22 (s, 1H), 7.25 (d, 1H), 7.41 (t, 1H), 8.05 (s,
1H), 8.7 (s, 1H), 11.0 (s, 1H), 11.5-11.8 (br s, 1H)
[0249] Triphenylphosphine (2.19 g, 8.36 mmol) was added to a
suspension of
(2-fluoro-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (1 g,
3.34 mmol) in methylene chloride (10 ml) cooled at 0.degree. C.,
followed by 1-(tert-butoxycarbonyl)-4-hydroxymethylpiperidine (1.08
g, 5.01 mmol), (prepared as described for the starting material in
Example 1), and diethyl azodicarboxylate (1.31 ml, 8.36 mmol).
After stirring for 2 hours at ambient temperature, the volatiles
were removed under vacuum. The residue was purified by column
chromatography eluting with methylene chloride/methanol (2/98).
After removal of the solvent by evaporation, the residue was
triturated with ether, collected by filtration, washed with ether
and dried under vacuum to give
7-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-4-(2-fluoro-4-methylanil-
ino)-6-methoxyquinazoline (327 mg, 20%).
[0250] MS-ESI: 497 [MH]+
[0251] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.15-1.3 (m, 2H); 1.45
(s, 9H); 1.8 (d, 2H); 2.0-2.1 (m, 1H); 2.4 (s, 3H); 2.75-2.9 (br s,
2H); 3.95 (s, 3H); 4.0 (br s, 2H); 4.05 (d, 2H); 7.1 (d, 1H); 7.15
(d, 1H); 7.2 (s, 1H); 7.4 (t, 1H); 7.85 (t, 1H); 8.32 (s, 1H); 9.45
(s, 1H)
EXAMPLE 9
[0252] A solution of
4-(4-bromo-2,6-difluoroanilino)-7-(1-(tert-butoxycarbonyl)piperidin-4-ylm-
ethoxy)-6-methoxyquinazoline (578 mg, 1 mmol) in methylene chloride
(10 ml) containing TFA (4 ml) was stirred at ambient temperature
for 2 hours. The volatiles were removed under vacuum and the
residue was suspended in water. The aqueous layer was adjusted to
approximately pH10 and was extracted with methylene chloride. The
organic layer was washed with water, brine, dried (MgSO.sub.4) and
the volatiles were removed by evaporation. The residue was
triturated with ether and dried under vacuum to give
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(piperidin
-4-ylmethoxy)quinazoline (110 mg, 23%).
[0253] MS-ESI: 479-481 [MH]+
[0254] .sup.1H NMR Spectrum: (DMSO-d.sub.6) 1.15-1.3 (m, 2H); 1.75
(d, 2H); 1.85-2.0 (br s, 1H); 2.5 (d, 2H); 3.0 (d, 2H); 3.97 (s,
3H); 4.0 (d, 2H); 7.2 (s, 1H); 7.62 (d, 2H); 7.82 (s, 1H); 8.35 (s,
1H)
[0255] .sup.1H NMR Spectrum: (DMSOd.sub.6; CF.sub.3COOD) 1.5-1.65
(m, 2H); 2.0 (d, 2H); 2.15-2.3 (br s, 1H); 3.0 (t, 2H); 3.4 (d,
2H); 4.02 (s, 3H); 4.15 (d, 2H); 7.4 (s, 1H); 7.75 (d, 2H); 8.1 (s,
1H); 8.92 (s, 1H)
[0256] The starting material was prepared as follows:
[0257] Sodium hydride (60%, 612 mg, 15.3 mmol) was added to a
solution of 4-bromo-2,6-difluoroaniline (2.77 g, 6.65 mmol) in DMF
(80 ml). After stirring for 30 minutes at ambient temperature,
7-benzyloxy-4-chloro-6-methoxyquinazoline (2 g, 6.65 mmol),
(prepared, for example, as described in WO 97/22596, Example 1, but
the free base was generated prior to use), was added and stirring
was maintained for 4 hours. The mixture was partitioned between
ethyl acetate and water (200 ml). The organic layer was separated,
washed with water, brine, dried (MgSO.sub.4) and the volatiles were
removed by evaporation. The residue was triturated with
isopropanol, collected by filtration, washed with ether and dried
under vacuum to give
7-benzyloxy-4-(4-bromo-2,6-difluoroanilino)-6-methoxyquinazoline
(1.95 g, 62%).
[0258] MS-ESI: 472-474 [MH].sup.+
[0259] .sup.1H NMR Spectrum: (DMSOd.sub.6) 3.94 (s, 3H), 5.3 (s,
2H), 7.3 (s, 1H), 7.4 (d, 1H), 7.45 (t, 2H), 7.5 (s, 1H), 7.55 (d,
1H), 7.65 (d, 2H), 7.85 (s, 1H), 8.35 (s, 1H), 9.4-9.6 (br s,
1H)
[0260] Using an analogous procedure to that described for the
synthesis of the starting material in Example 8,
7-benzyloxy-4-(4-bromo-2,6-difluoroanilino)-6-methoxyquinazoline
(1.9 g, 4.02 mmol) was reacted with TFA (20 ml) to give
4-(4-bromo-2,6-difluoroanilino)-7-hydroxy-6-methoxyquinazoline (1.5
g, 98%).
[0261] .sup.1H NMR Spectrum: (DMSOd.sub.6) 3.95 (s, 3H), 7.1 (s,
1H), 7.6 (s, 1H), 7.65 (s, 1H), 7.8 (s, 1H), 8.3 (s, 1H), 9.45 (br
s, 1H), 10.5 (br s, 1H)
[0262] Using an analogous procedure to that described in the
preparation of the starting material in Example 8,
4-(4-bromo-2,6-difluoroanilino)-7-hydroxy-6-methoxyquinazoline (1
g, 2.62 mmol) was reacted with
1-tert-butoxycarbonyl)-4-hydroxymethylpiperidine (845 mg, 3.93
mmol), (prepared as described for the starting material in Example
1), to give
4-(4-bromo-2,6-difluoroanilino)-7-(1-tert-butoxycarbonyl)piperidin-4-ylme-
thoxy)-6-methoxyquinazoline (620 mg, 41%).
[0263] MS-ESI: 579-581 [MH]+
[0264] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.15-1.3 (m, 2H); 1.45
(s, 9H); 1.8 (d, 2H); 2.0-2.1 (m, 1H); 2.7-2.9 (m, 2H); 3.95 (s,
3H); 4.0 (br s, 2H); 4.05 (d, 2H); 7.22 (s, 1H); 7.65 (d, 2H); 7.85
(s, 1H); 8.35 (s, 1H); 9.4-9.6 (br s, 1H)
EXAMPLE 10
[0265] Using an analogous procedure to that described in Example 9,
7-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-4-(4-chloro-2,6-difluoro-
anilino)-6-methoxyquinazoline (95 mg, 0.2 mmol) in methylene
chloride (2 ml) was treated with TFA (800 .mu.l) to give
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quina-
zoline (20 mg, 26%).
[0266] MS-ESI: 435-437 [MH]+
[0267] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.2-1.3 (m, 2H); 1.75
(d, 2H); 1.85-2.0 (br s, 1H); 2.5 (d, 2H); 3.0 (d, 2H); 3.97 (s,
3H); 4.0 (d, 2H); 7.2 (s, 1H); 752 (d, 2H); 7.85 (s, 1H); 8.35 (s,
1H)
[0268] The starting material was prepared as follows:
[0269] Using an analogous procedure to that described for the
preparation of the starting material in Example 9,
7-benzyloxy-4-chloro-6-methoxyquinazoline (184 mg, 0.61 mmol),
(prepared, for example, as described in WO 97/22596, Example 1, but
the free base was generated prior to use), was reacted with
4-chloro-2,6-difluoroaniline (200 mg, 1.22 mmol) in the presence of
sodium hydride (60%, 87 mg, 1.4 mmol) in DMF (8 ml) to give
7-benzyloxy-4-(4-chloro-2,6-difluoroanilino)-6-methoxyquinazoline
(212 mg, 74%).
[0270] MS-ESI: 428 [MH]+
[0271] .sup.1H NMR Spectrum: (DMSOd.sub.6) 3.96 (s, 3H); 5.31 (s,
2H); 7.32 (s, 1H); 7.4 (d, 1H); 7.45 (t, 2H); 7.5-7.6 (m, 4H); 7.85
(s, 1H); 8.35 (br s, 1H); 9.55 (br s, 1H)
[0272] A solution of
7-benzyloxy-4-(4-chloro-2,6-difluoroanilino)-6-methoxyquinazoline
(200 mg, 0.47 mmol) in TFA (3 ml) was stirred at 80.degree. C. for
3 hours. After cooling, the volatiles were removed under vacuum and
the residue was dissolved in water containing 5% methanol. The pH
was adjusted to 8 with sodium hydrogen carbonate and the solid was
collected by filtration and washed with water. The solid was
solubilised in a mixture of ethyl acetate/methanol/methylene
chloride (47/6/47). The volatiles were removed under vacuum to give
4-(4-chloro-2,6-difluoroanilino)-7-hydroxy-6-methoxyquinazoline
(126 mg, 80%).
[0273] MS-ESI: 338 [MH]+
[0274] .sup.1H NMR Spectrum: (DMSOd.sub.6) 3.95 (s, 3H); 7.1 (s,
1H); 7.55 (d, 2H); 7.8 (s, 1H); 8.3 (s, 1H); 9.42 (br s, 1H)
[0275] Using an analogous procedure to that described for the
preparation of the starting material in Example 9,
4-(4-chloro-2,6-difluoroanilino)-7-hydroxy-6-methoxyquinazoline
(150 mg, 0.44 mmol) was reacted with
1-(tert-butoxycarbonyl)-4-hydroxymethylpiperidine (150 mg, 0.88
mmol), (prepared as described for the starting material in Example
1), to give
7-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-4-(4-chloro-2,6-difluoro-
anilino)-6-methoxyquinazoline (113 mg, 59%).
[0276] MS-ESI: 535 [MH]+
[0277] .sup.1H NMR Spectrum: (DMSOd.sub.6) 1.15-1.3 (m, 2H); 1.45
(s, 9H); 1.8 (d, 2H); 2.0-2.1 (m, 1H); 2.7-2.9 (m, 2H); 3.95 (s,
3H); 4.0 (br s, 2H); 4.05 (d, 2H); 7.2 (s, 1H); 7.6 (m, 2H); 7.8
(s, 1H); 8.35 (s, 1H); 9.4-9.6 (br s, 1H)
EXAMPLE 11
[0278] The following illustrate representative pharmaceutical
dosage forms containing the compound of formula I, or a
pharmaceutically acceptable salt thereof (hereafter compound X),
for therapeutic or prophylactic use in humans: TABLE-US-00016 (a)
Tablet I mg/tablet Compound X 100 Lactose Ph. Eur 182.75
Croscarmellose sodium 12.0 Maize starch paste (5% w/v paste) 2.25
Magnesium stearate 3.0
[0279] TABLE-US-00017 (b) Tablet II mg/tablet Compound X 50 Lactose
Ph. Eur 223.75 Croscarmellose sodium 6.0 Maize starch 15.0
Polyvinylpyrrolidone (5% w/v paste) 2.25 Magnesium stearate 3.0
[0280] TABLE-US-00018 (c) Tablet III mg/tablet Compound X 1.0
Lactose Ph. Eur 93.25 Croscarmellose sodium 4.0 Maize starch paste
(5% w/v paste) 0.75 Magnesium stearate 1.0
[0281] TABLE-US-00019 (d) Capsule mg/capsule Compound X 10 Lactose
Ph. Eur 488.5 Magnesium stearate 1.5
[0282] TABLE-US-00020 (e) Injection I (50 mg/ml) Compound X 5.0%
w/v 1 M Sodium hydroxide solution 15.0% v/v 0.1 M Hydrochloric acid
(to adjust pH to 76) Polyethylene glycol 400 4.5% w/v Water for
injection to 100%
[0283] TABLE-US-00021 (f) Injection II (10 mg/ml) Compound X 1.0%
w/v Sodium phosphate BP 3.6% w/v 0.1 M Sodium hydroxide solution
15.0% v/v Water for injection to 100%
[0284] TABLE-US-00022 (g) Injection III (1 mg/mL, buffered to pH6)
Compound X 0.1% w/v Sodium phosphate BP 2.26% w/v Citric acid 0.38%
w/v Polyethylene glycol 400 3.5% w/v Water for injection to 100%
Note The above formulations may be obtained by conventional
procedures well known in the pharmaceutical art. The tablets
(a)-(c) may be enteric coated by conventional means, for example to
provide a coating of cellulose acetate phthalate.
* * * * *